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 ABSTRACT 
Small aggressive non-small cell lung carcinomas (SA-NSCLC) are characterized by 
spread to distant lymph nodes and metastases, even while the primary tumour remains 
small in size, as opposed to tumours that are relatively large before cancer progression. 
These small aggressive cancers present a challenge for clinical diagnosis and screening, 
carry grave prognosis, and may benefit from using a targeted approach to identify high-
risk individuals. The objectives of this thesis were to identify factors associated with SA-
NSCLC, and compare survivorship of stage IV SA-NSCLC to large stage IV NSCLC. 
Logistic and Cox regression analysis were performed using data from the National Lung 
Screening Trial (NLST). Model building was guided by knowledge of lung 
carcinogenesis and lung cancer prognostic factors. Previous diagnosis of emphysema and 
positive family history of lung cancer in females were associated with increased risk of 
SA-NSCLC among adenocarcinomas. Despite overall poor prognosis, SA-NSCLC have a 
better prognosis compared to large stage IV NSCLC. 
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CHAPTER I: INTRODUCTION 
Lung cancer is the leading cause of cancer death worldwide, and in most 
developed countries, despite a slow but consistent decrease in lung cancer rates in men. 
The same decrease is not yet been seen in women, due to cigarette smoking rates peaking 
two decades earlier in men than in women (Alberg, Brock, Ford, Samet, & Spivack, 
2013). Even still, more men than women will die of lung cancer each year, however, in 
much of the world the gender gap is narrowing (Alberg et al., 2013). Global statistics 
from 2008 showed that 13% of all new cancer diagnoses were cancers of the lung, 
however, lung cancer deaths represented 18% of cancer deaths (Alberg et al., 2013). The 
discordance between lung cancer incidence and mortality is likely related to the fact that 
nearly 70% of patients with lung cancer present with locally advanced or metastatic 
disease at time of diagnosis (Mirsadraee, Oswal, Alizadeh, Caulo, & van Beek, 2012).  
One of the best-characterized relationships in cancer etiology is that of cigarette 
smoking and lung cancer. Smoking has been identified as the primary cause of lung 
cancer, accounting for between 80-90% of cases, and smokers have a 10-30 fold 
increased risk of developing lung cancer compared to never smokers (Alberg et al., 2013; 
Dela Cruz, Tanoue, & Matthay, 2011). The relationship is further evidenced by the fact 
that lung cancer rates rise and fall with the rates of smoking. Frequency of histological 
subtypes of lung cancer shadow changes in cigarette chemical composition (Alberg & 
Samet, 2003; Wynder & Muscat, 1995). There are other risk factors that have been linked 
to lung cancer including socio-demographic, biological, genetic, and environmental 
factors, which will be detailed later in this thesis. 
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Lung cancer is typically classified into two types based on the lung cell-types that 
are involved in the carcinogenesis. The two types are small cell lung cancers (SCLC) and 
non-small cell lung cancers (NSCLC). NSCLC represent nearly 85% of all lung cancers, 
and can be further classified into three major subtypes as adeno-, squamous cell, and 
large cell carcinomas (Molina, Yang, Cassivi, Schild, & Adjei, 2009). Tumours are 
further characterized according to the Tumour-Node-Metastasis classification system as 
detailed by the American Joint Committee on Cancer, which is now in it’s 7th edition 
(Edge & Compton, 2010; Mirsadraee et al., 2012). T represents a measure of the tumour 
size and extension, N describes the spread of the cancer to regional lymph nodes, and M 
defines the metastases of neoplastic cells beyond regional lymph nodes (Mirsadraee et al., 
2012). Using the TNM system, cancers are sub-classified into one of four staging groups, 
each of which contain cancers with similar tumour characteristics and prognostic 
outcomes (Mirsadraee et al., 2012). The staging groups range from stage I to stage IV, 
with stage I representing early stage cancer, and stage IV representing advanced stage 
cancer, which has metastasized to other locations in the body. Accurate lung cancer 
staging is an integral part of the disease management process as it guides both treatment 
strategies, and assessment of prognosis (Mirsadraee et al., 2012). Advanced stage lung 
cancer is classically associated with larger tumour size, in association with spread to 
lymph nodes and metastases, and is associated with poor prognosis and increased 
mortality.  
1.1 High-Risk Population Screening 
 The goal of screening is to reduce lung cancer mortality. This is accomplished by 
identifying lung cancers earlier and shifting diagnosis to earlier stage disease, when 
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treatment options and prognosis are better. Recently low-dose helical computed 
tomography (LDCT) has been identified as an effective method to screen individuals for 
lung cancer, when compared to chest radiography (CXR) which has been found to be 
ineffective (National Lung Screening Trial Research Team, 2011a). Results from the 
National Lung Screening Trial (NLST) have found a 20% reduction in lung cancer 
mortality associated with screening with LDCT compared to CXR (National Lung 
Screening Trial Research Team, 2011a). In addition, the use of LDCT is most effective 
when screening is done on high-risk individuals (Tammemägi et al., 2013). Currently the 
NLST enrollment criteria are one definition used to identify high-risk individuals for 
screening. The criteria are: 55-74 years of age, with ≥30 pack-years history of smoking, 
or quit smoking ≤15 years prior (National Lung Screening Trial Research Team, 2011b). 
These criteria leave out known risk factors for lung cancer. More recently, the use of 
statistical prediction models, which take into account more known risk factors, have been 
found to be more sensitive in identifying high-risk individuals for screening (Tammemägi 
et al., 2013). As more risk factors for lung cancer continue to be identified, these factors 
may be used in selecting high-risk individuals who would most benefit from regular 
screening for lung cancer. 
1.2 Relationship Between Tumour Size and Outcome 
 The association between the size of tumours and disease outcome has remained 
somewhat controversial in the literature, as some researchers claim that tumour biology, 
and not tumour size, is the key determinant of tumour staging (Flieder et al., 2005). More 
recently, studies done by Yang et al., as well as by the International Early Lung Cancer 
Action Program Investigators (IELCAPI) have worked to identify the relationship 
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between tumour size and disease stage in lung cancers (International Early Lung Cancer 
Action Program Investigators, 2006; Yang et al., 2010). Using the TNM system, N0 and 
M0 diagnoses indicate no lymph node involvement and no distant metastases, 
respectively. Both studies compared the percentage of N0M0 lung cancers across strata of 
tumour sizes. Yang et al. found that 71% of <20 mm tumours, 59% of 20-30 mm tumours, 
48% of 30-50 mm tumours, 48% of 50-70 mm tumours, and 33% of >70 mm tumours, 
were considered N0M0 (Yang et al., 2010). Similar results were seen in the study done 
by the IELCAPI, 91% of <15 mm tumours, 83% of 16-25 mm tumours, 68% of 26-35 
mm tumours, and 55% of >36 mm tumours, were considered N0M0 (International Early 
Lung Cancer Action Program Investigators, 2006). Age and tumour size were both found 
to be associated with lung cancer stage, more advanced stage cancers were found in those 
younger than 60 years of age, and in those with larger tumours (Yang et al., 2010). 
Researchers from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening 
Trial (PLCO) reported observing a small but consistent proportion of NSCLC that were 
found to have spread to distant lymph nodes and metastasized, even while the primary 
tumour remained small in size, as opposed to tumours that are relatively large before 
progression (Tammemägi et al., 2007). Research done by Tammemägi et al. (2007) have 
characterized and identified factors related to these small aggressive cancers. In this 
previous study, “small” cancers were considered T1 (< 3 cm with minimal invasion of 
surrounding tissues) (Tammemägi et al., 2007). Using data from Yang et al. (2010), as 
much as 36% of small (< 3 cm) cancers have diagnoses beyond N0M0. These cancers 
that appear to be highly aggressive while the primary tumour remains relatively small in 
size, have been termed small aggressive non-small cell lung carcinomas (SA-NSCLC). 
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Small cell lung cancers are highly metastatic even while the primary tumour is relatively 
small in size. This characteristic is not generally true for NSCLC. For this reason, it is of 
particular interest to study what contributes to the aggressiveness of these NSCLCs; 
SCLC will not be included in the current research. Very little research has been done to 
describe the factors associated with these SA-NSCLCs. 
1.3 Risk Factors for SA-NSCLC & Gaps in Literature 
 Extensive research has been, and continues to be, done in the field of associative 
modeling and identification of risk factors related to the development of lung cancer, in 
both smokers and non-smokers. However, research is limited on characterizing and 
identifying the factors specifically associated with aggressive forms of lung cancer, and 
specifically these aberrant small aggressive forms. 
 Previous research by Tammemägi et al. started to characterize these small 
aggressive cancers. Risk factors identified for SA-NSCLC include: younger age at 
diagnosis (<65 versus ≥65), female sex, family history of lung cancer, and the sex by 
family history of lung cancer interaction. SA-NSCLC were found to be inversely 
associated with ibuprofen use. In addition, some risk factors were identified as promising 
in univariate analysis including histology (adenocarcinoma versus any other NSCLC), 
and inversely with both smoking duration squared, and history of heart disease/infarction. 
 While previous research has laid the groundwork in identifying factors related to 
SA-NSCLC, further research is needed to validate these findings and to elucidate other 
novel markers of this disease. The data used in the previous research was generated from 
the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), a 
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randomized screening trial, which used chest radiography (CXR) to screen individuals for 
lung cancer. More sensitive imaging modalities, such as low-dose helical computed 
tomography (LDCT), have been found to be more sensitive at identifying smaller 
tumours, and providing more accurate tumour measures, leading to increased 
identification of lung cancers. Gaps in knowledge remain as to whether or not the 
previously identified associations are histology specific. In addition, by making use of 
more accurate and precise tumour size measures from LDCT imaging, the gap of 
knowledge with respect to the lower bounds of tumour size for detecting SA-NSCLC can 
be addressed. 
1.4 Contributing New Knowledge & Response to Gaps in Literature 
 In order to address the current gaps in knowledge surrounding SA-NSCLC, the 
current study used data from the National Lung Screening Trial (NLST). The NLST is a 
large randomized screening trial funded the U.S. National Cancer Institute and will be 
described in more depth in subsequent chapters. In brief, the NLST was a multicenter 
study done to compare CXR with LDCT for screening of lung cancer in 53,452 
participants. The NLST dataset included many of the same variables contained in the 
PLCO dataset, which allowed the current research to validate previously identified or 
suspected risk factors of SA-NSCLC in a different population, while also working to 
identify novel markers of this disease. The current research served to validate a suspected 
heritable genetic component to SA-NSCLC by evaluating the interaction of sex with a 
family history of lung cancer. If further validated the results could offer insights into lung 
carcinogenesis, direct future avenues of research, and in the future possibly suggest 
methods for prevention and treatment. 
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1.5 Specific Aims 
 The specific aims of this research were 
1. To identify and characterize factors associated with SA-NSCLC. Specifically, to 
identify novel socio-demographic, biological, environmental, and lifestyle factor 
associations or effect modifications on the risk of developing SA-NSCLC. 
2. To validate previously identified risk factors for small aggressive cancers, in 
particular the sex-family history of lung cancer interaction. 
3. To investigate whether survival differences exist between stage IV SA-NSCLC 
and other stage IV NSCLC. 
As described previously, data from the NLST were used to address all of the study 
aims. In order to address the first two study aims, logistic regression analysis was used to 
compare SA-NSCLC to large non-aggressive NSCLC. SA-NSCLC were defined as lung 
cancer patients with T1 tumours (< 30 mm) that have spread to distant regional lymph 
nodes (N3), metastasized (M1), or both. Large non-aggressive NSCLCs were defined as 
patients with tumours larger than T1 (≥ 30 mm) and excluded individuals with locally 
aggressive disease (T4), distant nodal disease (N3), or metastases (M1) – thus the non-SA-
NSCLC group will consist of lung cancer cases with tumours T2 to T3, N0 to N2, and M0. 
For the third aim, survival analysis was used to compare SA-NSCLC to other stage IV 
NSCLCs for differences in survivorship. For survival analysis, both a dichotomous 
outcome variable (death due to lung cancer), and time-to-event data (time from diagnosis 
to death/censorship) were used. 
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1.6 Conclusion 
 This thesis worked to fill important gaps with respect to identifying factors related 
to an aggressive form of cancer that has an extremely poor prognosis. Identification of 
novel markers and validating previously identified associations could have clinical and 
public health implications in identifying high-risk individuals at risk of developing these 
small aggressive cancers. The small size of these cancers presents a challenge for clinical 
diagnosis and screening, both of which may benefit from taking a more targeted approach 
to high-risk populations. This study worked to corroborate and expand on previous 
research using higher quality lung tumour data. 
 Lung cancer remains a serious public health issue, with nearly 70% of lung cancer 
diagnoses at advanced stage metastatic or locally advanced disease. It is of upmost 
importance to continue to expand our knowledge of factors related to lung carcinogenesis, 
specifically related to the development of highly aggressive lung cancers. The results of 
this study may serve to guide future research, as well as advise screening and treatment 
protocol. These aberrant forms of lung cancer may involve unique biological pathways 
and characteristics when compared with cancers that follow a more traditional 
developmental pathway, such as primary tumours being relatively large before disease 
progression, and by furthering our understanding of these pathways may provide new 
insights into lung carcinogenesis. 
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CHAPTER II: REVIEW OF THE LITERATURE 
 
2.1 Overview 
 The current chapter provides the rationale and basis for this study. The chapter 
begins with an introduction to lung cancer, including details on etiology, pathology, 
histology, clinical features, and tumour characteristics. The chapter concludes by 
describing a previous study of SA-NSCLC, identifying known and suspected risk factors 
for lung cancer, as well as the importance of screening in reducing lung cancer mortality. 
2.2 Lung Cancer Biology  
2.2.1 Etiology & Pathogenesis 
Lung cancer is characterized by the development and proliferation of neoplastic 
cells arising in the epithelial cells of the lung (Dela Cruz et al., 2011). On a molecular 
level, cancer results from mutations, or a series of mutations, that can lead to rapid cell 
division, and potential invasion of surrounding tissue (Carney, 1988; National Cancer 
Institute, 2015b). This increase in cell proliferation, without cellular regulation or cell 
death (apoptosis), is caused by changes to genes that control these functions in normal 
cells (Carney, 1988). The genetic changes that contribute to the development of 
neoplastic cells tend to affect three different types of genes – proto-oncogenes, tumour-
suppressor genes, and DNA repair genes (National Cancer Institute, 2015b). Proto-
oncogenes are genes involved with the normal control of cell-growth and division in 
cells; however, alteration of these genes can lead to hyperactivity and become cancer-
causing oncogenes (National Cancer Institute, 2015b). Oncogenes are genes whose 
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products are involved in the development of cancer, many of which are mutated forms of 
normal genes (proto-oncogenes), which are involved in the control of cell-growth or 
division. Tumour suppressor genes are also involved in cell growth and proliferation by 
serving as inhibitors to cellular replication. Mutations to tumour-suppressor genes may 
lead to cell division in an uncontrolled manner by losing inhibitory abilities (National 
Cancer Institute, 2015b). DNA repair genes are associated with making repairs to DNA in 
cells. Mutations in these genes can lead to DNA not being repaired and mutations 
accumulating, and may include mutations in proto-oncogenes and tumour suppressor 
genes, which can lead to cells becoming cancerous (National Cancer Institute, 2015b). 
There is no singular cause of all types of lung cancer; the contributions of both exogenous 
and endogenous carcinogenic factors can lead to the genetic mutations that initiate the 
cancer pathway. The most commonly mutated genes involved in lung carcinogenesis 
include TP53, EGFR, KRAS, MET, LKB1, BRAF, PIK3CA, ALK, RET, and ROS1 
(Brennan, Hainaut, & Boffetta, 2011; El-Telbany & Ma, 2012). 
Uncontrolled cellular proliferation within the epithelial cells of the lung leads to 
development of tumours that can grow and invade nearby tissues (Dela Cruz et al., 2011). 
Primary tumours arising in the lung have potential to spread to the lymphatic system and 
lymph nodes, as well as spread to distant tissues (metastasis) (American Cancer Society, 
2015c). The physical presence of the tumour itself within the lung can cause problems by 
interrupting normal organ function – this problem can also occur in organs that develop 
secondary tumours occurring due to metastases from a primary lung tumour. 
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2.2.2 Histology 
For treatment and prognostic purposes, lung cancer is differentiated into two main 
histological types: small-cell lung cancer (SCLC), and non-small cell lung cancer 
(NSCLC) (Collins, Haines, Perkel, & Enck, 2007). Light microscopy and/or 
histochemical analysis can be used to further differentiate lung cancers into four major 
and several minor subtypes (Collins et al., 2007). The four major classes of lung cancer 
include SCLC, and subtypes of NSCLC, which include adenocarcinomas, squamous-cell 
carcinomas, and large-cell carcinomas (Collins et al., 2007). All four major histological 
subtypes are described in the following sections. Other forms of tumours can develop in 
the lungs; however, the majority of cases are small- and non-small cell cancers 
(American Cancer Society, 2015d). 
2.2.2.1 Small-Cell Lung Cancers 
 Small cell lung cancers (SCLC) are considered a distinct clinical and histological 
entity within the range of lung cancers (Van Meerbeeck, Fennell, & De Ruysscher, 2011). 
SCLC are described by van Meerbeeck et al. (2011) as “a malignant epithelial tumour 
consisting of small cells with scant cytoplasm, ill-defined cell borders, finely granular 
nuclear chromatin, and absent or inconspicuous nucleoli”. Typical or pure SCLC consists 
of only small cells, and represents 90% of SCLC cases, while combined tumours contain 
components of large cells (Collins et al., 2007; Van Meerbeeck et al., 2011). SCLC 
accounts for approximately 15% of all lung cancer cases (National Cancer Institute, 
2015a; Sher, Dy, & Adjei, 2008). In more industrialized countries, rates of SCLC have 
decreased over the past 30 years due to changes in smoking patterns, however, in 
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countries where smoking prevalence remains high so do the rates of SCLC (Van 
Meerbeeck et al., 2011). Smoking accounts for nearly 95% of all SCLC cases, and 90% 
of those who present with the disease are elderly current or former heavy smokers (Sher 
et al., 2008; Van Meerbeeck et al., 2011). Tumour characteristics of SCLC can be 
described using the TNM tumour classification system, however, more commonly and for 
treatment purposes they are often described as limited, or extensive stage (American 
Cancer Society, 2015b; Van Meerbeeck et al., 2011). Limited stage disease is defined as 
the disease confined to the ipsilateral hemithorax (one side of the chest), whereas 
extensive-stage disease is metastasis beyond the ipsilateral hemithorax (wide 
dissemination to contralateral lung or other locations) (American Cancer Society, 2015b; 
Collins et al., 2007). SCLC are clinically aggressive, centrally located with extensive 
mediastinal involvement and associated with early metastases (Collins et al., 2007). 
SCLC present with distinct clinical features such as bulky and centralized location on 
chest radiography (CXR), high initial response to chemotherapy, and high frequency of 
metastases (Van Meerbeeck et al., 2011).  
 SCLCs by their nature metastasize early, and therefore most are considered small 
aggressive lung cancers (SALC).  The same is not generally true for NSCLC; therefore it 
is of interest to understand what about NSCLC leads them to be SALCs. Additionally, 
due to the distinct characteristics of SCLC when compared to NSCLC, with differences 
in biology, pathophysiology, treatment, and survivorship, cases of SCLC were not 
included in the current study, which only focused on NSCLC cases. 
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2.2.2.2 Non-Small Cell Lung Cancers 
2.2.2.2.1 Large-Cell Carcinomas 
 Large-cell (undifferentiated) carcinomas represent approximately 10-15% of all 
lung cancers, and account for the smallest proportion of NSCLC when compared to 
squamous-cell and adenocarcinomas (American Cancer Society, 2015d). These types of 
cancers can develop in any location of the lung, though they tend to be peripherally 
located masses, and tend to grow and spread very quickly, which creates problems for 
both screening and treatment (American Cancer Society, 2015d; Collins et al., 2007).  
2.2.2.2.2 Squamous-Cell Carcinomas 
 Squamous cells are flat cells that line the inside of the airways (American Cancer 
Society, 2015d). Approximately 25-30% of all lung cancers are squamous-cell 
carcinomas. These cancers are typically centrally located in the lungs, near a bronchus, or 
within a main airway branch, and formed from reserve cells (round cells), replacing 
injured or damaged cells in the lining of the lungs major airways (College of American 
Pathologists, 2011b). This type of cancer is almost always caused by smoking (College of 
American Pathologists, 2011b). These cancers tend to be slow growing, with symptoms 
also developing slowly, and metastasize late in disease course (College of American 
Pathologists, 2011b; Collins et al., 2007). Up until the late 1970’s, squamous-cell 
carcinomas were the most common type of lung cancer, however, temporal changes in 
histopathologic subtype have seen a shift toward a predominance of adenocarcinomas, 
while squamous-cell carcinomas and SCLCs rates have decreased (Ozkaya, Findik, Atici, 
Kandemir, & Erkan, 2013).  
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2.2.2.2.3 Adenocarcinomas 
 Adenocarcinomas represent the most common form of lung cancer, mainly 
occurring in current or former smokers, but they are also the most common lung cancer in 
never smokers (College of American Pathologists, 2011a). These types of lung tumours 
are also more common in women than men, and are more likely to occur in younger 
individuals than other types of lung cancers (American Cancer Society, 2015d). 
Adenocarcinomas account for approximately 40% of all lung cancers, and arise in 
glandular cells that would become secretory cells under normal conditions (American 
Cancer Society, 2015d; College of American Pathologists, 2011a). These tumours tend to 
be peripherally located masses in the lungs, tend to grow slower than other types of lung 
cancer and are more likely to be found before metastases, however, they tend to 
metastasize earlier in disease course compared to squamous-cell carcinomas (American 
Cancer Society, 2015d; College of American Pathologists, 2011a; Collins et al., 2007).  
2.3 Treatments and Prognosis 
Treatment for lung cancer differs based on histologic type and disease stage. At 
time of diagnosis, approximately 30% of SCLC cases are limited-stage (National Cancer 
Institute, 2015a). Primary treatment of SCLC is typically chemotherapy, often 
accompanied with concurrent radiotherapy, however, despite responsiveness to 
chemotherapy, advanced stage at diagnosis carries a poor prognosis (Collins et al., 2007). 
SCLCs have a median survival time of 2-4 months, and five-year survival of 15-25% for 
limited-stage, and <5% for extensive-stage disease (Collins et al., 2007; Van Meerbeeck 
et al., 2011).  
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For NSCLCs, surgery is the treatment of choice for patients with stage I through 
IIIA lung cancer (Collins et al., 2007). In addition, pre- or postoperative chemotherapy 
with or without radiotherapy can be included as part of the treatment strategy (Collins et 
al., 2007). At time of diagnosis approximately 25% of lung cancer patients are candidates 
for surgical resection (Mirsadraee et al., 2012). For unresectable stage IIIA and IIIB lung 
cancers, primary treatment is chemotherapy with concurrent or subsequent radiotherapy 
(Collins et al., 2007). For advanced stage IIIB and IV lung cancers, primary treatment is 
chemotherapy with or without radiotherapy, and may include surgical resection of 
primary brain metastasis and/or primary T1 tumour (Collins et al., 2007). For non-small 
cell lung cancers, 5-year survival is 60-70% for Stage I, 40-50% for stage II, 15-30% for 
Stage IIIA (resectable), 10-20% for Stage IIIA (unresectable)/IIIB (involvement of 
contralateral or supraclavicular lymph nodes), and a 2-year survival of 10-15% for Stage 
IIIB (pleural effusion)/IV lung cancers (Collins et al., 2007). 
2.4 Small Aggressive Non-Small Cell Lung Carcinomas 
 Small aggressive non-small cell lung carcinomas were first identified and 
characterized by researchers using data from the Prostate, Lung, Colorectal, and Ovarian 
Caner Screening Trial (PLCO) (Tammemägi et al., 2007). These cancers were identified 
as having spread to distant lymph nodes and/or metastasized, even while the primary 
tumour remains small in size, as opposed to tumours that are relatively large before 
progression (Tammemägi et al., 2007). In previous research by Tammemägi et al. (2007), 
SA-NSCLC were defined as lung cancer patients with T1 tumours (<3 cm), that had 
spread to distant regional lymph nodes (N3), had metastasized (M1), or both. To identify 
novel risk factors for developing these small aggressive cancers, they were compared to 
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large non-aggressive cancers. Large non-aggressive cancers were defined as patients with 
tumours larger than T1 and excluded individuals with locally aggressive disease (T4), 
distant nodal disease (N3), or metastasis (M1) – thus the non-SA-NSCLC consisted of 
lung cancer cases with tumours T2 to T3, N0 to N2, and M0 (Tammemägi et al., 2007). 
 Previously identified risk factors for SA-NSCLC included younger age at 
diagnosis (<65 versus ≥65), ibuprofen use (yes versus no), female sex, family history of 
lung cancer, and sex*family history of lung cancer interaction (Tammemägi et al., 2007). 
Risk factors identified as having possible association in univariate modeling includes 
smoking duration, history of heart disease/infarction, and histology (adenocarcinoma 
versus other NSCLC) (Tammemägi et al., 2007). When comparing those diagnosed at 
≥65 years of age to those <65 years of age, it was found that age a diagnosis was 
associated with SA-NSCLC (OR=0.44; 95% CI: 0.22-0.88) (Tammemägi et al., 2007). 
The sex by family history interaction found that females with family history of lung 
cancer were significantly associated with SA-NSCLC (OR=7.39; 95% CI: 1.17-46.58) – 
validation of this finding may offer insight into elucidating the genetic and female 
hormone environment interaction and may contribute to our understanding of lung 
carcinogenesis (Tammemägi et al., 2007). Ibuprofen use was found to be inversely 
associated with SA-NSCLC (OR=0.29; 95% CI: 0.11-0.76) (Tammemägi et al., 2007). 
These small aggressive cancers carry a grave prognosis and increase mortality, as 
they are no longer surgically resectable with curative intent (Tammemägi et al., 2007). It 
is hypothesized that these SA-NSCLC may involve unique biological pathways, and this 
thesis will work to further our understanding of these cancers. 
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2.5 Clinical Features 
2.5.1 Signs and Symptoms 
 While about 10% of lung cancer cases are incidentally diagnosed in asymptomatic 
individuals, the majority of cases are found in patients presenting with manifestations of 
the cancer (Collins et al., 2007). Symptom onset for squamous-cell carcinomas and 
adenocarcinomas, which represent the majority of lung cancer cases, is rather slow, 
helping to explain why 70% of patients with lung cancer present with locally advanced or 
metastatic disease at time of diagnosis (Molina et al., 2009). Individuals with lung cancer 
may present with non-specific systemic symptoms such as fatigue, anorexia, or weight 
loss, or with systemic signs and symptoms directly attributable to the primary tumour, 
intrathoracic spread, extrathoracic spread, or paraneoplastic syndromes (Collins et al., 
2007). Manifestations related to the presence of the primary tumour include chest 
discomfort, cough, dyspnea, and hemoptysis (Collins et al., 2007). Forty percent of lung 
cancer patients present with signs and symptoms of intrathoracic spread including chest 
wall invasion, esophageal symptoms, Horner syndrome, Pancoast’s tumour, phrenic 
nerve paralysis, pleural effusion, recurrent laryngeal nerve paralysis, or superior vena 
cava obstruction (Collins et al., 2007). Nearly one third of lung cancer patients present 
with extrathoracic signs and symptoms including bone pain or fracture, confusion, 
personality change, elevated alkaline phosphatase levels, focal neurologic deficits, 
headache, nausea, vomiting, palpable lymphadenopathy, seizures, weakness, or weight 
loss (Collins et al., 2007). Approximately 10% of lung cancer patients present with signs 
and symptoms related to paraneoplastic syndromes due to release of bioactive chemicals 
produced by the tumour, or in response to the tumour (Collins et al., 2007). Certain signs 
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and symptoms of lung cancer can be misdiagnosed as pneumonia or a collapsed lung 
(College of American Pathologists, 2011a). 
2.5.2 Diagnosis 
 As described previously, only approximately 10% of lung cancers are diagnosed 
in asymptomatic patients, which can be detected via chest radiographs or suspected 
through routine examinations (Collins et al., 2007). For the vast majority of lung cancer 
cases, clinical indications and manifestations of signs and symptoms related to the disease 
indicate the need for some form of diagnostic follow-up to confirm diagnosis and stage of 
the disease. Physical examination and investigating patient history can often aid in the 
diagnostic process, however, various techniques for tissue diagnosis can often provide 
conclusive evidence of cancer (National Cancer Institute, 2014b). In suspected early stage 
NSCLC patients, who are believed to be surgical candidates, thoracotomy or needle 
biopsy are the recommended diagnostic tests for tissue diagnosis and staging (Collins et 
al., 2007). In individuals with suspected SCLC or metastatic NSCLC, the most 
convenient and least invasive procedures are preferred. These methods include 
thoracentesis of a pleural effusion, excisional biopsy of an accessible node, bronchoscopy, 
or transthoracic needle aspiration (Collins et al., 2007). In situations where the type and 
stage of cancer are not clear, other options exist for diagnosis – sputum cytology, flexible 
bronchoscopy, or transthoracic needle aspiration (Collins et al., 2007). The diagnostic 
accuracy of these techniques can vary according to tumour size, as well as the locale of 
the tumours (central versus peripheral) (Collins et al., 2007). Diagnosing lung cancer at 
an earlier stage can lead to more therapeutic options, which in turn can increase 
survivorship. This highlights the importance of striving to continue to identify risk factors 
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that may lead to the identification of high-risk individuals who would most benefit from a 
targeted screening approach. Recently screening initiatives have been implemented in 
order to shift the diagnosis of lung cancers to an earlier stage; these techniques and the 
results of some major studies will be discussed in subsequent sections. 
2.6 Tumour Staging 
2.6.1 Tumour-Node-Metastasis Cancer Staging System 
 Following or concurrently with diagnostic follow-up, accurate tumour 
classification and staging is of great importance for determining treatment options and 
prognosis. Non-small cell lung carcinoma characteristics are typically described by the 
Tumour-Node-Metastasis (TNM) tumour staging system as developed and maintained in 
a unified effort by the American Joint Committee on Cancer (AJCC) and the Union for 
International Cancer Control (UICC). The TNM system is used to describe T - the size of 
the primary tumour in long axis, or the direct extent of the tumour into adjacent 
structures; N – degree of spread to regional lymph nodes; M – presence of metastases 
beyond regional lymph nodes (Mirsadraee et al., 2012). A complete breakdown of the 7th 
edition of the TNM cancer staging system is described in Table 1. 
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Table 1. Tumour-Node-Metastasis (TNM) Cancer Staging System, 7th edition. (American 
Joint Commission on Cancer, 2010) 
Primary Tumour (T) 
TX Primary tumour cannot be assess, or tumour proven by the presence of 
malignant cells in sputum or bronchial washings but not visualized by imaging 
or bronchoscopy 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour 3 cm or less in greatest dimension, surround by lung or visceral 
pleura, without bronchoscopic evidence of invasion more proximal than the 
lobar bronchus (i.e., not in the main bronchus) 
T1a Tumour 2 cm or less in greatest dimension 
T1b Tumour more than 2 cm but 3 cm or less in greatest dimension 
T2 Tumour more than 3 cm but 7 cm or less or tumour with any of the following 
features (T2 tumours with these features are classified T2a if 5 cm or less); 
Involves main bronchus, 2 cm or more distal to the carina; Invades visceral 
pleura (PL1 or PL2); Associated with atelectasis or obstructive pneumonitis 
that extends to the hilar region but does not involve the entire lung 
T2a Tumour more than 3 cm but 5 cm or less in greatest dimension 
T2b Tumour more than 5 cm but 7 cm or less in greatest dimension 
T3 Tumour more than 7 cm or one that directly invades any of the following: 
parietal pleural (PL3) chest wall (including superior sulcus tumours), 
diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumour 
in the main bronchus (less than 2 cm distal to the carina; or associated 
atelectasis or obstructive pneumonitis of the entire lung or separate tumour 
nodule(s) in the same lobe 
T4 Tumour of any size that invades any of the following: mediastinum, heart, 
great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, 
carina, separate tumour nodule(s) in a different ipsilateral lobe 
  
Regional Lymph Nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and 
intrapulmonary nodes, including involvement by direct extension 
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) 
N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or 
contralateral scalene, or supraclavicular lymph node(s) 
  
Distant Metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Separate tumour nodule(s) in a contralateral lobe tumour with pleural nodules 
or malignant pleural (or pericardial) effusion 
M1b Distant metastasis 
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2.6.2 Stage Grouping 
 In addition to the cancer staging system described in the previous section, often 
times tumours with similar characteristics are grouped together to form staging groups 
that share similar prognosis, and treatment options (American Cancer Society, 2015a). 
Once TNM categories have been established, the information is used to assign an overall 
stage group of 0, I, II, III, or IV, some stages are subdivided into A and B (American 
Cancer Society, 2015a). Lower stage numbers correspond to better prognosis. A complete 
breakdown of the stage grouping is presented in Table 2. 
Table 2. Stage Grouping based on TNM Cancer Staging System. (American Joint 
Commission on Cancer, 2010) 
Stage Tumour status Nodal status Metastases 
Occult carcinoma TX N0 M0 
Stage 0 Tis N0 M0 
Stage IA T1a N0 M0 
 T1b N0 M0 
Stage IB T2a N0 M0 
Stage IIA T2b N0 M0 
 T1a N1 M0 
 T1b N1 M0 
 T2a N1 M0 
Stage IIB T2b N1 M0 
 T3 N0 M0 
Stage IIIA T1a N2 M0 
 T1b N2 M0 
 T2a N2 M0 
 T2b N2 M0 
 T3 N1 M0 
 T3 N2 M0 
 T4 N0 M0 
 T4 N1 M0 
Stage IIIB T1a N3 M0 
 T1b N3 M0 
 T2a N3 M0 
 T2b N3 M0 
 T3 N3 M0 
 T4 N2 M0 
 T4 N3 M0 
Stage IV Any T Any N M1a 
 Any T Any N M1b 
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2.6.3 Tumour Grade 
 Tumour cell samples can be taken during biopsy to provide further pathologic 
assessment of the tumour. For tumour grading, the degree of abnormality, as assessed by 
microscopy, can indicate how quickly a tumour will grow and spread (National Cancer 
Institute, 2013). If the cells of the tumour, as well as the organization of the tumours 
tissue are similar to normal cells and tissue, the tumour is considered “well-differentiated” 
(National Cancer Institute, 2013). Well-differentiated tumours are considered to have 
better prognosis, as they tend to grow and spread at a slower rate (National Cancer 
Institute, 2013). Tumours with highly abnormal looking cells, and lacking tissue structure, 
are considered “undifferentiated” or “poorly differentiated” (National Cancer Institute, 
2013). The grading system spans from G1 to G4, where higher numbers indicate less 
differentiation and worse prognosis (National Cancer Institute, 2013). The complete 
breakdown of tumour grading system can be seen in Table 3. 
Table 3. Tumour Grading System. (American Joint Commission on Cancer, 2010) 
Grade Description 
GX Grade cannot be assessed 
G1 Well differentiated (low grade) 
G2 Moderately differentiated 
G3 Poorly differentiated 
G4 Undifferentiated (high grade) 
 
2.6 Lung Cancer Statistics 
 Lung cancer is the leading cause of cancer death worldwide, as well as in Canada 
(Alberg et al., 2013; Statistics Canada, 2014). Nearly 2 out of every 5 Canadians will 
develop cancer in their lifetime with lifetime probabilities of 45% and 41% for males and 
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females, respectively (Statistics Canada, 2014). It is estimated that 191,300 new cases of 
cancer will develop in Canada in 2014, with breast, lung, colorectal, and prostate cancer 
accounting for 52% of incident cases of cancer (Statistics Canada, 2014). Age-
standardized incidence rates of cancer in Canada between 2001-2010 rose by 0.5% per 
year for females, and decreased 1.3% per year for males (Statistics Canada, 2014). Some 
of the increase in incidence of cancer in Canada can be attributed to changes in diagnostic 
and screening techniques over time, however, decreases in some cancers can be attributed 
to limiting exposure to carcinogenic risk factors such as tobacco, and alcohol (Statistics 
Canada, 2014). Lung cancers account for approximately 13.7% of new cancers in males, 
and approximately 13.3% of new cancers in females (Statistics Canada, 2014). Temporal 
and spatial trends in lung cancer incidence tend to follow a 20-year lag behind smoking 
patterns (Alberg et al., 2013). In Canada, incidence rate of lung cancer in males leveled 
off in the mid-1980’s, and has begun to decline ever since at a rate of nearly 2% per year 
(Statistics Canada, 2014). For females in Canada, incidence rates have stopped increasing 
since 2006; however, overall incidence rates are still higher among males than females 
(Statistics Canada, 2014). These differences in trends in incidence rates can be attributed 
to past differences in tobacco use, with male smoking rates peaking in the mid-1960’s, 
and in females in the mid-1980’s (Statistics Canada, 2014). Smoking rates in women 
started to decline in the 1980’s and rates of lung cancer are expected to decline over the 
coming years. In Canada the smoking prevalence in those aged 15+ years is 16.1% 
(Statistics Canada, 2014). The age-adjusted incidence rate of lung cancer in both sexes is 
52 per 100,000, and is 59 per 100,000 in males, and 48 per 100,000 in females (Statistics 
Canada, 2014). 
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 In both Canada and the US it is estimated that 1 out of every 4 people will die 
from cancer (Siegel, Naishadham, & Jemal, 2013; Statistics Canada, 2014). In Canada, 
lung cancer is the third most common incident cancer in males, and second most common 
in females (Statistics Canada, 2014). With respect to cancer-related mortality, lung cancer 
mortality is number one for both sexes, representing 27.0% and 26.5% of cancer death in 
males and females, respectively (Statistics Canada, 2014). High mortality for lung cancer 
is closely related to the fact that nearly 70% of patients diagnosed with lung cancer 
present with locally advanced or metastatic lung cancer, and at this point treatment 
options are limited and prognosis is poor (Molina et al., 2009). The overall 5-year 
survival for lung cancer is approximately 15% in Canada (Statistics Canada, 2014). 
Survivorship is heavily dependent on both age and disease stage (Collins et al., 2007; 
Statistics Canada, 2014). 
2.8 Etiologic & Prognostic Risk Factors 
 In order to address the study aims of the proposed research it is important to gain 
an understanding of the risk factors suspected or known to have a relationships with lung 
cancer. With the objective of identifying factors associated with small aggressive cancers, 
as well as identifying factors that modify survivorship, current suspected risk factors will 
be explored to help provide the basis for possible inclusion of these factors in model 
building for this thesis. In the following section risk factors will be divided into two 
overarching categories, modifiable, and non-modifiable risk factors. Modifiable or 
lifestyle risk factors can be changed, while non-modifiable risk factors are either very 
difficult to, or cannot be, changed. 
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2.8.1 Modifiable Risk Factors 
2.8.1.1 Smoking 
 Since the mid-20th century lung cancer has been causatively associated with 
cigarette smoking and tobacco use (Wynder & Muscat, 1995). This relationship has been 
found to be causative both with active smoking, as well as passive (secondhand) smoking 
(Alberg et al., 2013). Despite the fact that constellations of risk factors have been 
identified as associated with lung cancer development, smoking remains the primary 
single factor. Smoking accounts for approximately 80-90% of lung cancer incidence 
worldwide, and a 10-30 fold increase in relative risk when comparing long-term smokers 
to lifetime never-smokers (Alberg et al., 2013; Dela Cruz et al., 2011). Smoking can 
cause all four of the main lung cancer histologic subtypes (Alberg et al., 2013; Ozkaya et 
al., 2013). Few environmental exposures convey such a risk to a disease. Both cigar and 
pipe smoking also show casual relationships with lung cancer, however, less so due to 
differences in frequency of use, and depth of inhalation of smoke (Alberg et al., 2013).  
The nature of the relationship between different smoking measures and lung 
cancer incidence has been found to vary when comparing smoking duration with smoking 
intensity. A model by Doll & Peto was developed to quantify how changing duration and 
intensity affect lung cancer risk, and found a linear relationship between cigarettes per 
day (intensity) and lung cancer risk (i.e. triple the number of cigarettes per day, triple the 
risk of lung cancer), meanwhile for smoking duration, the relationship was found to be 
exponential (i.e. triple the smoking duration, nearly 100-fold increased risk of lung 
cancer) (Alberg, Ford, & Samet, 2007). It is important to note that individual 
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susceptibility matters for lung cancer. Between 80-90% of lung cancer occurs in persons 
exposed to tobacco smoke, however, only around 20% of smokers develop lung cancer 
(Dela Cruz et al., 2011). Individual susceptibility to smoking-related lung cancer is likely 
modulated by genetic predisposition, and interaction with other environmental factors 
(Dela Cruz et al., 2011). It is estimated that approximately 20% of worldwide cancer-
related death could be eliminated if complete smoking cessation was achieved (Dela Cruz 
et al., 2011).  
Typical cigarette smoke contains many potential carcinogens including polycyclic 
aromatic hydrocarbons (PAHs), aromatic amines, N-nitrosamines, and other organic and 
inorganic compounds, including benzene, vinyl chloride, arsenic, and chromium (Dela 
Cruz et al., 2011). In addition, radioactive materials including radon and its decay 
products, bismuth and polonium, are also found in tobacco smoke (Dela Cruz et al., 
2011). The International Agency for Research on Cancer (IARC) has identified 50+ 
carcinogenic agents in tobacco smoke; of particular concern for lung carcinomas are 
tobacco-specific N-nitrosamines (TSNAs), which occur through nitrosation of nicotine 
during smoking (Dela Cruz et al., 2011). For some chemical compounds, such as PAHs 
and N-nitrosamines, metabolic activation or detoxification can take place and determine 
whether these chemicals become carcinogenic metabolites – it is possible that the balance 
between activation and detoxification is related to individual susceptibility related to 
genetic polymorphisms (Dela Cruz et al., 2011). 
 Secondhand smoking (SHS) has consistently been linked with increased risk of 
lung cancer, with studies finding a 25-29% increase in risk of lung cancer for non-
smokers married to a smoker (Alberg et al., 2007). Workplace secondhand smoke 
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exposure has been found to increase risk of lung cancer nearly 17% (Alberg et al., 2007). 
Studies on SHS provide further evidence of a dose-response relationship between 
smoking and lung cancer. Increased risk of lung cancer is observed even at low dosage 
levels seen in secondhand smokers, indicating no threshold. Results from a meta-analysis, 
and a comprehensive review have found relative risks (RR) of 1.14-5.20 in never-
smokers living with smokers; and secondhand smoke during childhood had a 3.6-fold 
increased risk of lung cancer (Molina et al., 2009). 
Smoking cessation has been found to decrease the overall risk of lung cancer 
when compared to continuing smokers (Alberg et al., 2007). Rates of lung cancer are 
lower in former smokers, when compared to current smokers, however, even >40 years of 
smoking abstinence has a higher risk of lung cancer compared to lifetime never-smokers 
(Alberg et al., 2007). Smoking is by far the most important modifiable risk factor when it 
comes to lung cancer risk. 
2.8.1.2 Environmental & Occupational Carcinogens 
2.8.1.2.1 Asbestos 
 Asbestos is a naturally occurring fibrous silicate commonly used commercially in 
acoustic or thermal insulation, and household exposure occurs through installation, 
degradation, removal, or repair of asbestos containing products (Roshni, Purushothaman, 
Reghu, & Vijayan, 2015). Asbestos can be categorized into two groups, both of which 
have been linked to the development of lung cancer (Field & Withers, 2012; Roshni et al., 
2015). The first class of asbestos is known as serpentine, and its only constituent 
chrysotile is a widely used form of asbestos (Roshni et al., 2015). The second class of 
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asbestos is known as the amphiboles, which contains amosite, crocidolite, anthophyllite, 
actinolite, and tremolite types of asbestos (Roshni et al., 2015). Amphiboles have been 
linked with a stronger biological effect on the pleura and peritoneum (Roshni et al., 2015). 
Asbestos is considered the most common occupational cause of lung cancer, despite the 
fact that the exact mechanism remains unclear (Alberg et al., 2013). Controversy 
surrounds whether asbestos serves as a direct carcinogen, or acts through indirect 
mechanisms, such as through chronic lung inflammation that promotes cancer 
development (Alberg et al., 2013). Asbestos is considered an independent risk factor for 
lung cancer, but acts synergistically with smoking creating marked increases in lung 
cancer risk (Alberg et al., 2013). Additionally, research suggests that asbestos alone is 
carcinogenic independent of asbestosis (Dela Cruz et al., 2011). Exposure to asbestos has 
been found to increase the risk of lung cancer nearly 3.5-fold after age, smoking, and diet 
adjustment, and has a standardized mortality ratio (SMR) of 1.96 (95% CI: 1.7-2.2) for 
lung cancer death (Field & Withers, 2012). Non-occupational asbestos-related lung 
cancer is very rare, despite ubiquitous exposure to asbestos for individuals in 
industrialized countries (Dela Cruz et al., 2011). Certain fiber types, as well as longer 
(>10 μm) and thinner (<0.25 μm) fibers, have been suspected to increase risk of lung 
cancer, however, IARC believes this observed effect is likely associated with differences 
in exposure measures, and not due to fiber type or dimensions (Field & Withers, 2012). 
2.8.1.2.2 Ionizing Radiation 
 Two types of radiation, generally classified by the rate of energy transfer to 
tissues, are of particular relevance to lung carcinogenesis. The two types are: low linear 
energy transfer (LET) radiation (e.g., x-rays, γ-rays), and high-LET (e.g., radon/α-
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particles) (Alberg et al., 2013). High-LET radiation produces ionization of higher density 
in tissues when compared to low-LET radiation, and given similar doses high-LET 
radiation produces more biologic damage (Alberg et al., 2013). 
2.8.1.2.2.1 Radon (α-particles) 
 Radon is a colorless, inert, noble gas that is produced as a uranium decay product 
(Alberg et al., 2013). The gaseous radon is radioactive and if inhaled can emit high-
energy α-particles that can cause damage to the DNA of respiratory epithelium (Alberg et 
al., 2013). Alpha particles emitted from radon have the ability to produce a higher relative 
rate of double-stranded DNA breaks compared with other types of radiation (Field & 
Withers, 2012). Primary cells and nearby cells hit by α-particles can undergo genetic 
changes and lead to cancer (Field & Withers, 2012). In addition, α-particles can produce 
reactive oxygen intermediates that can cause oxidative damage to DNA (Field & Withers, 
2012). Genetic damage to a single bronchial cell can initiate cancer – cancer is thought to 
originate from a single cell that has completed the process of malignant transformation, 
therefore no threshold likely exists for α-particle induced lung cancer (Field & Withers, 
2012). Radon is an independent causal factor in lung carcinogenesis, however, radon can 
act synergistically with smoking to produce a multiplicative effect on lung cancer risk 
(Alberg et al., 2013). As much as 15,000 to 25,000 lung cancer deaths per year in the US 
are attributed to radon exposure (Alberg et al., 2013). 
2.8.1.2.2.2 X-rays and γ-rays 
 The majority of exposure to x-rays and γ-rays in the general population are due to 
medically related exposure (Field & Withers, 2012). Main contributors to x-ray exposure 
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include CT scans (24%), interventional fluoroscopy (7%), and conventional radiography 
and fluoroscopy procedures (5%), while the more recent use of nuclear medicine 
procedures (e.g., inhalation of technetium-99m for lung scans) contributes to γ-ray 
exposure (Field & Withers, 2012). At lower levels of exposure the change in risk is best 
modeled with a dose-dependent linear relationship (Alberg et al., 2013). In the US, a 
substantial portion of the population is exposed to ionizing radiation, particularly to CT 
scans, and in large enough an amount to cause population excess of cancer (Alberg et al., 
2013). The effects of ionizing radiation on cancer risk have largely been studied in atomic 
bomb survivors in Japan, those with diseases leading to treatment with multiple radiation 
exposures, and occupationally exposed groups (Alberg et al., 2013). Relative to never-
smokers, the joint effect of smoking and radiation was found to be super-multiplicative 
for light-moderate smokers with a rapid increase in risk up to 10 cigarettes per day (Field 
& Withers, 2012). For pack-a-day smokers the joint effect was approximately additive 
(Field & Withers, 2012). 
2.8.1.2.3 Biomass Emissions 
 Biomass is used in many parts of the world as a primary fuel for cooking and 
heating (Dela Cruz et al., 2011). Biomass (solid-fuel) sources can include any of the 
following: coal, crop residues, wood, sticks, or twigs. Inhalation of smoke from biomass 
combustion is found to increase the risk of lung cancer (Dela Cruz et al., 2011). Lung 
cancers that developed from wood-smoke exposure have been found to behave differently 
than those developed from tobacco smoke exposure, and can be an important factor in 
predicting responses to tyrosine-kinase inhibitor therapy in NSCLC (Dela Cruz et al., 
2011). Recently the International Agency for Research on Cancer (IARC) classified 
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indoor emissions from household coal combustion as a human carcinogen, and emissions 
from biomass fuel as a probable human carcinogen (Dela Cruz et al., 2011). Data from 
IARC were used to determine the odds of exposure to various biomass sources between 
individuals with and without lung cancer. When comparing those with lung cancer to 
those without, odds ratios of predominantly wood, coal, and lifetime solid-fuel exposure 
were 1.21, 1.64 (4.93 for coal users in Asia), and 1.80, respectively, relative to that of 
non-solid fuel use (Dela Cruz et al., 2011). The association between lung cancer and 
biomass smoke inhalation is weaker than that of fossil fuel burning (Alberg et al., 2013). 
2.8.1.2.4 Air Pollution/Particulate Matter 
 Many hazardous and potentially carcinogenic agents can be found within the air 
in the form of particulate matter. Some of the agents include combustion products from 
fossil fuels, PAHs, sulfur dioxide, nitrogen dioxide, and metals such as arsenic, nickel, 
and chromium (Alberg et al., 2013; Molina et al., 2009). The long-term effects from 
cumulative exposure to ambient air pollution have been known to contribute to 
respiratory disease, and also in respiratory carcinogenesis and increased risk of lung 
cancer (Molina et al., 2009). The mechanism by which the inhalation of airborne 
carcinogens is linked to lung cancer has not been entirely elucidated, however, is believed 
to operate by one or a number of the following physiological responses: oxidative stress, 
inflammation, induction of procoagulatory state, or dysfunction of autonomic nervous 
system (Molina et al., 2009). In Europe it is estimated that as much as 11% of lung cancer 
is attributable to urban air pollution (Molina et al., 2009). Results from the ACS Cancer 
Prevention Study II found that each 10 g/m3 increase in the concentration of fine particles 
in the air was associated with an increased risk of lung cancer by 14% (Alberg et al., 
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2013). Diesel exhaust has been found to increase the risk of lung cancer between 30-50%, 
while no such evidence is available yet linking gasoline exhaust to lung cancer risk (Dela 
Cruz et al., 2011). In 2014, Hamra et al. conducted a meta-analysis to assess the 
relationship between the exposure to particulate matter and the risk of lung cancer across 
17 cohort studies, and 1 case-control study (Hamra et al., 2014). Particulate matter (PM) 
was grouped two ways, particles with an aerodynamic diameter ≤2.4 μm were considered 
fine particles (PM2.5), while an aerodynamic diameter of ≤10 μm were considered 
inhalable particles (PM10) (Hamra et al., 2014). The groups were chosen this way as they 
are believed to differ in human health effects – fine particles are able to penetrate deeper 
in the respiratory system, and a higher proportion of fine particles are mutagenic species 
(Hamra et al., 2014). Relative risks for PM2.5 and PM10 exposure were 1.09 (95% CI: 
1.04-1.14) and 1.08 (95% CI: 1.00-1.17), respectively (Hamra et al., 2014). Further 
subset analysis by smoking status revealed that the risk of lung cancer associated with 
PM2.5 exposure differed by smoking status (Hamra et al., 2014). The risk was highest in 
former smokers (RR=1.44; 95% CI: 1.04-2.01), followed by never-smokers (RR=1.18; 
95% CI: 1.00-1.39), and a small non-statistically significant risk in current smokers 
(RR=1.06; 95% CI: 0.97-1.15) (Hamra et al., 2014). One issue associated with these 
results is that the smoking intensity and duration in former smokers was not assessed and 
may confound these results (Hamra et al., 2014). Subset analysis for histologic subtype 
(adenocarcinoma versus other NSCLC) found that the risk of adenocarcinomas was 
higher in PM2.5 exposed individuals (RR=1.40; 95% CI: 1.07-1.83), compared to 
individuals with PM10 exposure (RR=1.29; 95% CI: 1.02-1.63), though both indicate an 
elevated risk (Hamra et al., 2014). 
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2.8.1.3 Obesity & Body Mass Index 
 Body Mass Index (BMI) is a commonly used anthropometric construct combining 
both body height and weight, in relative terms, to serve as a measure of body composition. 
BMI is typically expressed in units of kilograms (kg) per squared height in meters (m2). 
In 2008, a meta-analysis by Renehan et al. examined the relationship between BMI and 
incident cases of cancer across 20 different cancer types (Renehan, Tyson, Egger, Heller, 
& Zwahlen, 2008). For lung cancer, results from 11 studies found a RR of 0.76 (95% CI: 
0.70-0.83) for men, and results from 6 studies found a RR of 0.80 (95% CI: 0.66-0.97) 
for women, for a 5 kg/m2 increase in BMI (Renehan et al., 2008). These results indicate 
an inverse association between BMI and incidence of lung cancer, and that the effect may 
be slightly greater in men than in women, however, there was much heterogeneity in 
results between studies (Renehan et al., 2008). Further analysis revealed that the inverse 
relationship was strongest among smokers, and was not present in non-smokers (Renehan 
et al., 2008). When results from the individual studies were assessed, as the proportion of 
smokers per study increased, so too did the strength of the association (Renehan et al., 
2008). This suggests possible confounding from smoking on the relationship between 
BMI and lung cancer, as smoking is associated with lower BMI among age and sex 
matched persons, as well as a primary risk factor in the development of lung cancer (Dela 
Cruz et al., 2011; Renehan et al., 2008). A study of women found that when adjusted for 
pack-years of smoking, and other relevant covariates, an inverse relationship existed 
between BMI and lung cancer in current/former smokers, while no significant association 
existed for never-smokers (Dela Cruz et al., 2011). Some of the observed association 
between BMI and lung cancer may be a consequence of residual confounding due to 
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smoking. While research on other measures of obesity have not been as thoroughly 
described as BMI, some results have found a positive association between waist 
circumference, a measure of abdominal adiposity, with lung cancer risk in smokers (Dela 
Cruz et al., 2011). 
2.8.1.4 Exercise & Physical Activity 
 Physical activity has been found to have an inverse association with lung cancer 
risk – physically active individuals have lower risk of lung cancer compared to those 
physically inactive (Alberg et al., 2013; Molina et al., 2009). Those who engage in 
moderate to high physical activity have been found to have a 13-30% reduction in lung 
cancer risk (Alberg et al., 2013; Molina et al., 2009). The specific mechanism that 
explains the potential effect is still unknown, however, given the relationship between 
tobacco use and physical activity, residual confounding by tobacco use may be an 
alternative explanation for the observed effect (Alberg et al., 2013). Overall increased 
levels of physical activity may play a role in reducing lung cancer risk and mortality 
among smokers (Molina et al., 2009). 
2.8.1.5 Diet & Nutrition 
 The role of diet and nutrition in cancer development has been primarily focused 
on its potential preventative role, though some research highlights possible increases in 
risk attributable to specific dietary factors. It has been suggested that diet may be 
responsible for 30% of all cancers, and that dietary factors can contribute to lung cancer 
development (Dela Cruz et al., 2011). Diets rich in fruit and vegetable consumption have 
been implicated as having a protective effect for lung cancer, however, this is a 
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contentious topic within the literature (Alberg et al., 2013; Dela Cruz et al., 2011; Molina 
et al., 2009; Willett & Trichopoulos, 1996). The protective effect appears to be stronger 
in current smokers versus former, and through the consumption of raw fruits and 
vegetables compared to cooked (Dela Cruz et al., 2011). Low or no intake of fruits or 
vegetables has been found to have a 3-fold risk of lung cancer (Dela Cruz et al., 2011). 
Much remains unknown about the possible protective effect of fruits and vegetables, 
though it is believed to be associated with being rich in antioxidants and other 
micronutrients, specifically carotenoids (Molina et al., 2009). Possible protective effects 
have been suggested for the following micronutrients: β-cryptoxanthin, lutein, zeaxanthin, 
lycopene, α-carotene, Vitamin A, Vitamin C, Vitamin E, and β-carotene (Dela Cruz et al., 
2011; Molina et al., 2009). Vitamin A has both an animal (retinol) and a vegetable 
(carotenoid) source. Only the vegetable source has be found to show protective effects 
(Dela Cruz et al., 2011). Previously β–carotene was suggested to be the most protective, 
however, the results of three large randomized, double-blinded placebo-controlled trials 
(CARET, ATBC, PHS) have added uncertainty to role of β-carotene in lung 
carcinogenesis (Alberg et al., 2013; Dela Cruz et al., 2011). The β-carotene and Retinol 
Efficacy Trial (CARET) enrolled 18,314 men and women, and was shut down due to no 
benefit and a clear risk associated with β-carotene intake (Dela Cruz et al., 2011). The 
Alpha-Tocopherol, Beta Carotene Cancer Prevention Study (ATBC) enrolled 29,133 
male smokers, and found increased mortality in the β-carotene group (Dela Cruz et al., 
2011). Finally, the Physicians’ Health Study (PHS) enrolled 22,071 male physicians and 
found no effect of β-carotene, though doses were lower than the other two studies (Dela 
Cruz et al., 2011). Previously saturated fats had been found to have a deleterious effect 
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with respect to lung cancer, however, more recently literature suggests no association 
between total or specific fat intake on lung cancer risk, independent of smoking status 
(Molina et al., 2009; Willett & Trichopoulos, 1996). Limited evidence suggests an 
increased risk of cancer associated with cured meats, deep-fried cooking, and chili 
(Molina et al., 2009). Overall the role of diet and nutrition on lung cancer risk isn’t 
entirely clear. Further research is needed to clarify ambiguous results in the literature. 
2.8.1.6 Alcohol 
 A meta-analysis by Freudenheim et al. (2005) assessed the relationship between 
alcohol and lung cancer risk by conducting pooled analysis of 7 prospective studies of 
399,767 subjects, with 3137 cases of lung cancer. The highest level of alcohol 
consumption (≥30 g alcohol/day) had a RR of 1.21 (95% CI: 0.91-1.61) for men, and RR 
of 1.16 (95% CI: 0.94-1.43) for women, when compared to those who abstain from 
alcohol consumption (0 g alcohol/day), and indicates and increased risk of lung cancer 
associated with high levels of alcohol consumption (Freudenheim et al., 2005). Among 
never-smokers, consumption of ≥15 g alcohol/day compared to abstainers was found to 
have an increased risk of lung cancer in men (RR=6.38; 95% CI: 2.74-14.9), however, for 
women, very few never-smoker lung cancer cases were present and no significant effect 
was seen (RR=1.35; 95% CI: 0.64-2.87) (Freudenheim et al., 2005). Similar to the 
observed relationships between obesity, diet and nutrition, and physical activity with lung 
cancer, it is difficult to disentangle the concomitant effects of smoking from alcohol 
consumption – those who consume alcohol tend to smoke more (Alberg et al., 2013; 
Freudenheim et al., 2005). Overall it appears there is a positive association between 
alcohol consumption and lung cancer risk, particularly in the highest consumption groups, 
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and in never-smoking males (Alberg et al., 2013; Freudenheim et al., 2005; Molina et al., 
2009). 
2.8.2 Non-Modifiable Risk Factors 
2.8.2.1 Age 
 The average age of most populations in developed countries is increasing, and 
cancer is considered a disease of the elderly (Dela Cruz et al., 2011). Smoking prevalence 
is lowest amongst 65+ year olds at 9.3%, when compared with 18-24, 25-44, and 45-64 
year olds at 21.4%, 23.7%, and 22.6%, respectively (Dela Cruz et al., 2011). Smoking 
prevalence, however, fails to account for former smoking patterns, and despite the lowest 
smoking levels amongst the oldest age group, the incidence of lung cancer remains 
highest, accounting for 65% of lung cancer patients, with the mean age at time of 
diagnosis at around 70 years (Dela Cruz et al., 2011). The disparity between smoking 
prevalence and lung cancer incidence may be attributable to heavy smoking histories in 
the current elderly population, however, age is considered a risk factor independent of 
smoking, and the most important predictor in never-smokers (Dela Cruz et al., 2011). The 
5-year survival rate for lung cancer decreases with age in both sexes (Dela Cruz et al., 
2011). Functionally fit elderly with lung cancer and a life expectancy > 5 years may 
benefit from aggressive treatment options typically used on younger patients, such as 
surgery for early stage disease, and single-agent chemotherapy for advanced stage disease 
(Dela Cruz et al., 2011). 
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2.8.2.2 Sex 
As described previously, smoking rates for women peaked nearly 20 years later 
than men, and have contributed to a similar lag in incidence rates (Alberg et al., 2013). 
There is controversy in the literature with respect to sex-specific susceptibility to 
smoking-related lung cancer, while some studies have found differential susceptibility to 
smoking-related lung cancer in males and females, with females have a greater 
susceptibility, others found males had higher susceptibility (Kiyohara & Ohno, 2010; Yu 
et al., 2014). Other studies found that for comparable smoking histories, rates of lung 
cancer remain similar between both sexes (Alberg et al., 2007; Bain et al., 2004). The 
specific biological and physiological mechanism by which sex-specific susceptibility to 
lung cancer may occur is not clear and needs to be researched further. 
 Lung cancer is more common among never-smoking women than never-smoking 
men, with rates being more than twice as high (Dela Cruz et al., 2011). The reason why is 
not clear, though certain speculation surrounding sex-differences in susceptibility and 
metabolism of non-tobacco environmental carcinogens, or increased exposure to second-
hand smoke have been considered possibilities (Dela Cruz et al., 2011). In addition, it 
appears there is a hormonal role with respect to lung cancer in women (Dela Cruz et al., 
2011). Estrogen replacement therapy (ERT) has been found to be associated with lung 
cancer risk (OR=1.7), and the interactive effect of ERT and smoking has shown a 
significant multiplicative effect (OR=32.4) in some studies (Dela Cruz et al., 2011). 
Additionally, early menopause (menopause before 40 years of age) has been found to 
have a protective effect on lung cancer risk (OR=0.3) (Dela Cruz et al., 2011). Despite 
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some evidence of an increased lung cancer risk associated with ERT, the relationship is 
not clearly established, and findings within the literature are mixed. 
 Adenocarcinomas has been found to be the most common histological type of 
lung cancer in both sexes, however, women still have a disproportionately higher 
proportion of adenocarcinomas (59.5% versus 48.2%) (Visbal et al., 2004). Men have 
higher mortality following diagnosis when compared to women (RR=1.20; 95% CI: 1.11-
1.30), especially for those with later stage disease (stage III/IV) (Visbal et al., 2004). The 
improved survival seen in women remains even after consideration for age, smoking 
history, tumour histology, grade, stage, comorbid conditions, treatment, and causes of 
death (Visbal et al., 2004). Overall being male is considered an unfavorable prognostic 
factor. 
2.8.2.3 Race/Ethnicity 
 The racial and ethnic disparities seen in lung cancer incidence rates, mortality 
rates, and survivorship are often intertwined with a strong socioeconomic component 
(Dela Cruz et al., 2011; Ward et al., 2004). Despite this, it appears that while some racial 
and ethnic disparities seem to be narrowing, differences still exist (Dela Cruz et al., 2011). 
Rates of lung cancers among African American women and white women are similar, 
however, there is a nearly 47% increase in the rates of lung cancer for African American 
men, compared to white men, and this trend holds true across all age-groups (Alberg et 
al., 2013; Dela Cruz et al., 2011). The racial and ethnic risk is not only associated with 
incidence rates of lung cancer, but mortality rates, as well (Alberg et al., 2013). Some of 
the racial/ethnic gap appears to be narrowing, with differences in lung cancer mortality of 
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42% in 1990 between African American and white American men, down to 25% in 2008 
(Alberg et al., 2013). A decrease in youth smoking among African American’s since the 
1970’s is believed to explain some of this narrowing in racial disparity (Alberg et al., 
2013). Initially, racial and ethnic lung cancer differences were attributed to differences in 
smoking prevalence, however, differences remained among certain races/ethnicities with 
similar smoking histories. An increased smoking-related lung cancer risk in African 
Americans may still be contributing to the observed increased incidence rates (Alberg et 
al., 2013; Dela Cruz et al., 2011; Haiman et al., 2006). An 8-year prospective study done 
by Haiman et al. between 1993 and 2001 looked at 183,813 individuals, with 1979 
incident cases of lung cancer (Haiman et al., 2006). Various racial and ethnic groups were 
compared for risk of lung cancer across strata of smoking intensity groups, as determined 
by number of cigarettes smoked per day (Haiman et al., 2006). An increased risk of lung 
cancer was found for African American and Native Hawaiian’s who smoke 21-30 
cigarettes per day (Haiman et al., 2006). For individuals who smoked no more than 10, or 
11-20 cigarettes per day, RR varied from 0.21 to 0.39 (p<0.001) for Japanese Americans, 
and Latinos, and between 0.45-0.57 (p<0.001) for whites, when compared to African 
Americans (Haiman et al., 2006). No significant differences in RR were found for the 
highest level of smoking intensity, greater than 30 cigarettes per day (Haiman et al., 
2006). This may indicate a smoking intensity threshold that masks any racial or ethnic 
differences due to the known deleterious effects of intense smoking on lung 
carcinogenesis. 
 In addition to differences in lung cancer incidence, differences in survival appear 
to exist between certain racial and ethnic groups (Ward et al., 2004). Asians have been 
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found to have better lung cancer survival when compared to whites, while this result is 
not entirely understood, one suspected contributing factor is differences in tumour 
characteristics (Alberg et al., 2013). Lung tumours in Asians have increased prevalence 
of epidermal growth factor receptor (EGFR) mutations when compared to whites – 
EGFR+ tumours are more responsive to some treatments, which may explain some of the 
improved survival (Alberg et al., 2013). Even after census tract, a marker of 
socioeconomic status, is taken into account, African American, American Indian/Alaskan 
Native, and Asian/Pacific Island men, along with African American and American 
Indian/Alaskan Native women have decreased 5-year survival compared to non-Hispanic 
white men and women (Ward et al., 2004). 
2.8.2.4 Socioeconomic Status (SES) 
 Socioeconomic status (SES) or socioeconomic position (SEP) are terms used to 
describe the social standing of an individual or group, and often measured as a 
combination of education, income, and occupation. SES is an oft-used indicator related to 
various health outcomes (Sidorchuk et al., 2009; Ward et al., 2004). Sidorchuk et al 
(2009) defines SEP as “…a multidimensional construct comprising a range of social 
circumstances that could affect health through different pathways, including accessibility 
of healthcare, exposure to various environmental factors, health behavior, and lifestyle” 
(Sidorchuk et al., 2009). A systematic review and meta-analysis done by Sidorchuk et al. 
included 64 studies that examined the individual and pooled effects of three components 
of SEP: educational, occupational, and income position (Sidorchuk et al., 2009). 
Educational position tends to be achieved relatively early on in life and begins to form 
health attitudes and behaviors, while also being associated with occupational choices, and 
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income levels, as well as access to health care (Sidorchuk et al., 2009). Occupational 
position can be associated with an increased risk of exposure to occupational carcinogens, 
and incomplete knowledge of the synergistic effects with other lifestyle habits, such as 
smoking, on lung cancer risk (Sidorchuk et al., 2009). Finally, income position has 
substantial interplay with education and occupation, and lower income reflects higher 
rates of unhealthy behaviors including smoking and poor diet, as well as less access to 
health care (Sidorchuk et al., 2009). When comparing lowest to highest SEP, lowest 
educational position, lowest occupational position, and lowest income position were 
associated with 61%, 48%, and 37% increase in lung cancer risk, respectively (Sidorchuk 
et al., 2009). Meta-RR incidence estimates from unadjusted and smoking adjusted studies 
of lowest versus highest education SEP were 1.65 (95% CI: 1.41-1.92), and 1.65 (95% 
CI: 1.19-2.28), respectively (Sidorchuk et al., 2009). Meta-RR incidence estimates from 
unadjusted and smoking adjusted studies of lowest versus highest occupation SEP were 
1.72 (95% CI: 1.40-2.11), and 1.33 (95% CI: 1.14-1.55), respectively (Sidorchuk et al., 
2009). Meta-RR incidence estimates from unadjusted and smoking adjusted studies of 
lowest versus highest income SEP were 1.48 (95% CI: 0.93-2.36), and 1.25 (95% CI: 
0.93-1.70), respectively (Sidorchuk et al., 2009). Lower educational and occupational 
position were associated with increased risk of lung cancer, and results remained 
significant after adjustment for smoking, however, much heterogeneity existed between 
pooled estimates. 
Lung cancer as a disease is most likely to occur in the poorest and least educated 
populations, however, much of this can be explained by trends in smoking that are 
disproportionately represented by those socioeconomic groups (Alberg et al., 2013). In 
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Canada, lung cancer risk is inversely associated with income, education, and social class, 
and despite universal health care being available to all, lower SES is associated with 
poorer lung cancer survival (Alberg et al., 2013). Lower SES is associated with later 
stage disease at diagnosis, leading to poorer survival, and is also associated with 
unfavorable interacting factors such as smoking, diet, and exposure to occupational and 
environmental carcinogens (Alberg et al., 2013). 
2.8.2.5 Genetic Susceptibility 
 Identification of genes that contribute to lung cancer can be important in 
understanding the underlying mechanisms of the disease, disease onset, survival, and may 
guide therapeutic treatment options (Brennan et al., 2011). Recently, three large 
collaborative genome-wide association studies (GWAS) have identified three gene loci 
associated with lung cancer: 5p15, 6p21, and 15q25 (Brennan et al., 2011). These genes 
regulate acetylcholine nicotinic receptors and telomerase production, and along with 
other suspected gene variants, may play a role in lung carcinogenesis (Brennan et al., 
2011). In addition, research suggests that some of the identified genes associated with 
lung cancer may have a synergistic effect with smoking as part of a gene-environment 
interaction (Brennan et al., 2011). Much about the genetic risk remains unknown for lung 
cancer, even less so with respect to the development and progression of aggressive lung 
tumours. 
2.8.2.6 Familial Aggregation 
 Through the use of family studies, segregation studies, linkage analysis, and both 
candidate gene and genome-wide association studies there has been substantial evidence 
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suggesting a heritable component to lung cancer (Gao et al., 2009). Familial aggregation 
of lung cancers amongst relatives has consistently demonstrated a higher risk of lung 
cancer for an individual (Gao et al., 2009). While these results likely indicate a genetic 
contribution associated with an increased familial risk, it could also be due to the familial 
clustering of non-genetic risk factors, such as smoking habits (Brennan et al., 2011). It 
has been estimated, however, that a familial tendency to smoke should increase risk of 
lung cancer by about 20%. This amount of increase does not fully account for the 
observed increase in familial risk, and suggests other factors, such as genetic 
susceptibility, may also contribute (Brennan et al., 2011). Results from a study using data 
from the Swedish Cancer Registry found that when looking at the ratio of observed 
incident cases of lung cancer among first-degree relatives, compared to the expected 
frequency (λ) that risk of lung cancer is 1.9 (95% CI 1.6-2.4) times higher (Brennan et al., 
2011). This value is similar to that of other cancers suspected of also having a familial 
component – breast (λ=1.5), colon (λ=1.9), and prostate (λ=2.7) (Brennan et al., 2011). 
Additionally, risk was higher amongst siblings (λ=3.1) than offspring (λ=1.6) (Brennan et 
al., 2011). 
 Overall, risk of lung cancer increases when there is a positive family history of 
lung cancer (Matakidou, Eisen, & Houlston, 2005). The risk is increased in relatives of 
cases diagnosed at a younger age and with multiple affected family members (Matakidou 
et al., 2005). A study by Lissowska et al. found that a positive family history of lung 
cancer was associated with an OR of 1.63 (95% CI: 1.31-2.01), and 2+ family members 
affected had an OR of 3.60 (95% CI: 1.56-8.31) (Lissowska et al., 2010). Previous 
research on small aggressive NSCLC have also elucidated a possible sex by family 
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history of lung cancer interaction, therefore it is important to consider the potential 
heritable contribution to aggressive lung cancers (Tammemägi et al., 2007). 
2.8.2.7 Acquired Lung Diseases 
 The deleterious nature of inflammatory processes on tissue has been suggested as 
playing a role in carcinogenesis (Brenner, McLaughlin, & Hung, 2011). Acquired lung 
diseases, such as chronic obstructive pulmonary disease (COPD) (emphysema or chronic 
bronchitis), adult pneumonia, and tuberculosis, can be sources of inflammation in the 
lungs and bronchus (Brenner et al., 2011). Presence of these conditions have been found 
to play a role in lung carcinogenesis, and related to lung tumour development through 
common etiologies and/or exposures, such as smoking (Brenner et al., 2011). A meta-
analysis and systematic review by Brenner et al. have looked at the previous lung 
diseases as risk factors for lung cancer development. When adjusted for smoking, 
previous history of COPD, chronic bronchitis, and emphysema had relative risks of 2.22 
(95% CI: 1.66-2.97), 1.52 (95% CI: 1.25-1.84), and 2.04 (95% CI: 1.72-2.41), 
respectively (Brenner et al., 2011). For subjects with previous history of pneumonia the 
RR was 1.43 (95% CI: 1.22-1.68), and for previous history of tuberculosis the RR was 
1.76 (95% CI: 1.49-2.08) (Brenner et al., 2011). In a subset analysis of never-smokers the 
combined COPD/chronic bronchitis/emphysema effect became non-statistically 
significant with a RR of 1.22 (95% CI: 0.97-1.53). Interestingly, the increased risk 
associated with previous history of pneumonia and tuberculosis remained with a RR of 
1.36 (95% CI: 1.10-1.69), and 1.90 (95% CI: 1.45-2.50), respectively (Brenner et al., 
2011). The results of this meta-analysis indicate increased risk of lung cancer among 
those with previous history of lung disease, and provide evidence of the role of 
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inflammation in lung carcinogenesis, particularly among smokers (Brenner et al., 2011). 
Possible proposed mechanisms by which an inflammatory response could contribute to 
carcinogenesis are through increased genetic mutations, anti-apoptotic signaling, and 
increased angiogenesis (Brenner et al., 2011). 
2.8.2.8 Infections 
 The relationship between infections and lung carcinogenesis is still surrounded by 
controversy and limited data (Alberg et al., 2013; Dela Cruz et al., 2011). While limited 
evidence is available, suspected relationships with lung cancer exist for Epstein-Barr 
virus, BK virus, John Cunningham (JC) virus, human cytomegalovirus, simian virus 40, 
measles virus, Torque teno virus, and Chlamydia pneumonia infections (Dela Cruz et al., 
2011). Recently human papillomavirus (HPV) has been found to cause carcinomas in 
other tissues, and HPV DNA has been isolated in squamous cell carcinomas of the lung 
(Alberg et al., 2013; Dela Cruz et al., 2011). There is a suspected relationship for the role 
of HPV in lung carcinogenesis, however, due to mixed evidence further research is 
necessary (Alberg et al., 2013; Dela Cruz et al., 2011). The greatest body of evidence for 
the relationship between infections and lung cancer is for individuals with human 
immunodeficiency virus (HIV) infection. Due to the advent of highly active antiretroviral 
treatments, AIDS-related mortality has dropped, however, this has led to an increase in 
deaths attributable to non-AIDS-defining tumours, such as lung cancer (Dela Cruz et al., 
2011). Lung cancer is third most common cancer in HIV infected individuals, only 
behind AIDS-defining cancers: Kaposi sarcoma, and non-Hodgkin’s lymphoma (Alberg 
et al., 2013). Thus, lung cancer is the most common non-AIDS-defining tumour, and 
accounts for nearly 16% of all deaths in HIV infected individuals (Alberg et al., 2013). In 
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general, patients with HIV infection and lung cancer are significantly younger than 
normal lung cancer patients (Alberg et al., 2013). When comparing those with HIV 
infection to those without, relative risks of between 2 to 11 have been reported (Alberg et 
al., 2013). These results are subject to bias due to failure to adjust for the confounding 
effect of tobacco use, and more realistic estimates of RR based on conservative tobacco 
use fall to around 2.5 (Alberg et al., 2013). The majority of HIV infected individuals with 
lung cancer present in advanced stage, and when compared to non-infected individuals 
with advanced stage lung cancer, have significantly shorter survival time (3-6 months 
versus 10-12 months) (Alberg et al., 2013). The shorter survival is due in part to the 
nature of HIV/AIDS, whereby immunosuppression limits treatment options, and nearly 
one quarter of patients remain untreated for their lung cancer (Alberg et al., 2013). HIV 
infection appears to carry an increased risk of lung cancer, independent of smoking status. 
More evidence is needed for other infections. 
2.9 Lung Cancer Screening 
 With the majority of lung cancer patients presenting with advanced stage disease 
when prognosis is poor, mortality is high, and the ability to treat cancer with curative 
intent is minimal, it becomes extremely important from a public health and clinical 
perspective to improve screening modalities for earlier lung cancer detection (Bach et al., 
2007; Mirsadraee et al., 2012). Wood et al. have defined the goals of screening as 
needing to improve outcomes, be scientifically validated, low-risk, reproducible, 
accessible, and cost-effective (Wood et al., 2012). This section details both the advances 
in lung cancer screening protocol, and the importance of accurate identification of high-
risk populations for screening. Previously, lung cancer screening involved the use of 
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chest radiography (CXR). Studies found that despite the increased identification of 
smaller and earlier stage lung cancers with CXR, there was no similar decline in detection 
of advanced stage cancers or a decrease in lung cancer mortality (Bach et al., 2007; 
Humphrey et al., 2013). This is likely due to CXRs inability to identify small cancers. 
More recently, the use of low-dose helical computed tomography (LDCT) has arisen as 
an effective method for regular screening of high-risk individuals for lung cancer due to 
the ability of LDCT to identify smaller nodules than CXR (Bach et al., 2012). 
 When LDCT was initially considered as a superior method to CXR in lung cancer 
screening, some systematic reviews conducted at the time found that despite the increase 
in diagnoses with LDCT, there was no appreciable decrease in mortality (Bach et al., 
2007; Humphrey et al., 2013). The increasing body of evidence from the completion of 
large randomized screening trials, such as the NLST, now suggests that regular annual 
screening with LDCT can be effective in reducing all-cause and lung cancer-specific 
mortality (Bach et al., 2012; Humphrey et al., 2013; National Lung Screening Trial 
Research Team, 2011a; Wood et al., 2012). One of the highest-quality and largest 
screening trials to date is the National Lung Screening Trial, which found that annual 
screening with LDCT showed a 20% decrease in lung cancer mortality compared to 
annual screening with CXR over a median of 6.5 years of follow-up (National Lung 
Screening Trial Research Team, 2011a).  Three other RCTs, the DANTE, MILD, and 
DLCST studies, have found no statistically significant differences in lung cancer 
mortality between LDCT and CXR (DANTE: RR=0.83; 95% CI: 0.45-1.54; DLCST: 
RR=1.37; 95% CI: 0.63-2.97; MILD: RR=1.99; 95% CI: 0.80-4.96) (Bach et al., 2012; 
Humphrey et al., 2013). Differences in mortality between the studies may be accounted 
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for due to inadequate sample size (DANTE), differential incomplete follow-up (DLSCT, 
MILD), differences in sample demography, and inadequate randomization (DANTE, 
MILD) (Humphrey et al., 2013). 
Despite the benefits of regular screening with LDCT for lung cancer detection, 
there are harms that need to be considered. Firstly, as with CXR, subjects are exposed to 
radiation. Based on estimates of radiation dosage per screening, the benefits of screening 
outweigh the potential risk of cumulative radiation, however, for those whom have low 
risk of developing lung cancer, such as non-smokers and younger individuals, the risks 
may outweigh the benefits of the long term effects of radiation (Bach et al., 2012; 
Humphrey et al., 2013). Complications of follow-up diagnostic procedures are another 
risk of screening, particularly among those without lung cancer undergoing a follow-up 
surgical intervention (Bach et al., 2012; Humphrey et al., 2013). For individuals with 
nodules determined to be benign, death and complications still occurred, and had higher 
rates of each when compared to chest radiograph groups (Bach et al., 2012; Humphrey et 
al., 2013). In association with complications of follow-up, false positive detection of 
abnormalities is an issue due to the ability of LDCT to detect very small cancerous and 
benign nodules. Many studies have reported more than 90% of nodules detected are 
benign, and approximately 1.2% of NLST false-positives were subject to invasive follow-
up techniques such as needle biopsy or bronchoscopy, while 0.7% of false-positives had a 
thoracoscopy, mediastinoscopy, or thoracotomy (Bach et al., 2012). Another issue with 
LDCT is overdiagnosis. LDCT can diagnose cancers that would otherwise not have 
become clinically apparent, or the individual would have died first of competing causes. 
Overdiagnosis for CXR has been estimated as high as 25% (Bach et al., 2012; Humphrey 
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et al., 2013). Estimates for overdiagnosis associated with LDCT are approximately 18% 
(Patz et al., 2013). Lastly, quality of life (QOL) can be affected by regular screening, one 
study found that while the majority report little or no discomfort from the actual 
procedure (88 to 99%), 46% report psychological stress while waiting for results (Bach et 
al., 2012). Harm can be caused by anxiety, costs, and by follow-up evaluation of false-
positive and overdiagnosed cancers (Bach et al., 2012). Humphrey et al. (2013) have also 
identified that no gold standard for negative results yet exists. Sensitivity of LDCT has 
been reported as ranging from 80-100%, with a false-negative rate of 0-20%. Increases in 
nodule size for positive criteria would increase specificity, but subsequently decrease 
sensitivity (Humphrey et al., 2013). A risk of false assurance of a negative result is also 
possible, however, no studies have investigated this harm (Humphrey et al., 2013). 
Looking at the benefits and the harms associated with LDCT, it is clear that 
further research needs to be done to be able to better identify those at highest risk for 
developing lung cancers that would most benefit from screening. As a result of the 
findings of the NLST, several organizations have begun to recommend using LDCT to 
screen high-risk individuals for lung cancer. Most of these recommendations base their 
definition of high risk on the NLST criteria of 55-74 years of age, ≥30 pack-years history 
of smoking, and former smokers having quit smoking ≤15 years prior, or some variant of 
these criteria (National Lung Screening Trial Research Team, 2011a; Tammemägi & 
Lam, 2014). These criteria, however, leave out known factors that are associated with 
lung cancer development. Risk-prediction models, that include more risk factors, have 
been shown to be more efficient at identifying high-risk individuals for screening 
(Tammemägi et al., 2014). A summary of the risks and benefits associated with lung 
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cancer screening can be seen in Table 4. 
Table 4. Risks/Benefits of Lung Cancer Screening, adapted from Wood et al. 
(2012). 
RISKS BENEFITS 
 Futile detection of small aggressive 
tumours or indolent disease 
 Decreases lung cancer mortality 
 Quality of life  Quality of life 
o Anxiety of test findings o Reduction in disease-related 
morbidity 
 Physical complications from diagnostic 
workup 
o Reduction in treatment-related 
morbidity 
 False-positive results o Improvement in health 
lifestyles 
 False-negative results o Reduction in 
anxiety/psychosocial burden 
 Unnecessary testing  Cost-effectiveness 
 Radiation exposure  
 Cost  
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CHAPTER III – METHODS 
3.1 Introduction 
 This chapter describes the study methods and design. Included in this chapter are 
the details surrounding the source data for this research including details on recruitment, 
endpoints, screening process, ethical approval and patient consent, and data collection 
methods. The chapter concludes with a description of the specific analytic and evaluative 
strategies that were used within the study to address the study aims presented in the 
previous chapters. 
3.2 Source Data – National Lung Screening Trial (NLST) 
 The current research was conducted using data collected from the National Lung 
Screening Trial (NLST) - a large randomized screening trial conducted by the U.S. 
National Cancer Institute (NCI). The NLST is a multicenter RCT that was done to 
compare low-dose helical computed tomography (LDCT) with single-view 
posteroanterior chest radiography (CXR) in screening of current and former smokers for 
early detection of lung cancer (National Lung Screening Trial Research Team, 2011a, 
2011b). The NLST was a collaborative effort of the Lung Screening Study (LSS), 
administered and funded by the NCI Division of Cancer Prevention, and by the American 
College of Radiology Imaging Network (ACRIN), administered and funded by the NCI 
Division of Cancer Treatment and Diagnosis, Cancer Imaging Program (National Lung 
Screening Trial Research Team, 2011a). The rationale for the study has been described 
elsewhere (National Lung Screening Trial Research Team, 2011b). 
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3.2.1 Ethical Approval & Informed Consent 
 Each screening center that contributed to the NLST received institutional review 
board approval before the onset of recruitment (National Lung Screening Trial Research 
Team, 2011b). Participants who were eligible for the study were required to sign an 
informed consent form (National Lung Screening Trial Research Team, 2011b). 
3.2.2 Recruitment and Participant Cohort 
 Enrollment began in August 2002. Participants for NLST were recruited by and 
enrolled at 33 screening centers across the United States. The target number of 
participants for recruitment was 50,000, however, rapid and successful recruitment 
resulted in an extra 3,452 participants. Recruitment goals were reached in April 2004 
(National Lung Screening Trial Research Team, 2011b). Potential participants were made 
aware of the trial through numerous methods including direct mailings and use of mass 
media - each screening center was responsible for their own recruitment practices 
(National Lung Screening Trial Research Team, 2011b). Interested participants contacted 
the screening centers on a volunteer basis (National Lung Screening Trial Research Team, 
2011b). In total, NLST enrolled 53,452 participants into the study (National Lung 
Screening Trial Research Team, 2011a). 
3.2.3 Inclusion & Exclusion Criteria 
 Eligibility criteria to be enrolled into the study included being between 55-74 
years of age, 30 or more pack-years of cigarette smoking, former smokers having quit 
within the previous 15 years, the ability to lie on the back with arms raised over the head, 
and ability and willingness to sign an informed consent form (National Lung Screening 
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Trial Research Team, 2011b). A number of criteria existed to exclude individuals from 
enrolling in the study. Exclusion criteria included: metallic implants or devices in the 
chest or back, treatment for, or evidence of, any cancer other than nonmelanoma skin 
cancer or carcinoma in situ, personal history of cancer within the last 5 years, history of 
removal of any portion of the lung, excluding needle biopsy, requirement for home 
oxygen supplementation, participation in another cancer screening trial, participation in a 
cancer prevention study, unexplained weight loss, recent hemoptysis, pneumonia or acute 
respiratory infection treated with antibiotics within 12 months, and chest CT examination 
in the past 18 months (National Lung Screening Trial Research Team, 2011b). 
3.2.4 Randomization and Screening Process 
Randomization of participants was approximately equal in proportions across the 
two study arms (National Lung Screening Trial Research Team, 2011b). Blocked 
randomization was used with stratification according to age, sex, and screening center 
(National Lung Screening Trial Research Team, 2011b). Participants were approximately 
equally distributed between the two screening arms (CT: 26,722; CXR: 26,730) (National 
Lung Screening Trial Research Team, 2011b). 
Participants were assigned to undergo three annual screenings with one of the two 
imaging modalities, one baseline screening shortly after randomization, and two annual 
screenings at 1-year intervals (National Lung Screening Trial Research Team, 2011b). 
After randomization all participants completed a questionnaire covering many areas 
including demographic characteristics, and smoking behavior (National Lung Screening 
Trial Research Team, 2011b). Some centers collected information on quality of life and 
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smoking cessation, while 15 centers provided serial blood, sputum, and urine specimens 
(National Lung Screening Trial Research Team, 2011b). Lung-cancer and other tissue 
specimens were collected by both ACRIN and LSS centers. All chest radiographic and 
low-dose CT scanners were approved and certified for use in the NLST, meeting NLST 
protocol requirements (National Lung Screening Trial Research Team, 2011b). The final 
screening round was completed in the summer of 2007 (National Lung Screening Trial 
Research Team, 2011b). 
3.2.5 Diagnostic and Therapeutic Follow-Up 
 Everyone with a diagnosis of lung cancer had screening stopped (National Lung 
Screening Trial Research Team, 2011b). Results and recommendations from the 
interpreting radiologists were reported to participants and their health care providers 
(National Lung Screening Trial Research Team, 2011b). Some trial radiologists 
developed guidelines for diagnostic follow-up, but no approach was mandated by NLST 
(National Lung Screening Trial Research Team, 2011b). Those with abnormalities 
suspicious of lung cancer received further contact. Following lung cancer diagnosis, the 
participant’s health care provider determined diagnostic work-up (National Lung 
Screening Trial Research Team, 2011b). Screening centers maintained close contact with 
participants and monitored medical records to obtain information on diagnostic 
evaluation, adverse effects, and treatment (National Lung Screening Trial Research Team, 
2011b). 
3.2.6 Endpoints 
 The primary endpoint for the NLST is lung cancer mortality, however, the two 
study arms were also compared on overall mortality (all-cause mortality), lung cancer 
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incidence, lung cancer case survival, lung cancer stage distribution, and screening and 
treatment-related morbidity (National Lung Screening Trial Research Team, 2011b). 
Endpoints were reviewed and verified by a panel of independent experts, blinded to the 
randomization arm (National Lung Screening Trial Research Team, 2011b). Substudies 
of NLST further assessed health care utilization, quality of life, and cost-effectiveness 
(National Lung Screening Trial Research Team, 2011b). For the research being proposed 
in the current study, specifically identified lung cancer cases will be used and described 
in subsequent sections. 
3.2.7 Data Collection 
 All participants were either annually (LSS participants) or semi-annually (ACRIN 
participants) sent a questionnaire regarding vital status (National Lung Screening Trial 
Research Team, 2011a). Participants who were lost to follow-up had their Social Security 
numbers submitted to National Death Index to identify probable vital status (National 
Lung Screening Trial Research Team, 2011a). Death certificate information was 
collected for those known to be dead; an endpoint verification team was used to identify 
if lung cancer was the cause of death, or if the death resulted from diagnostic evaluation 
or treatment of lung cancer (National Lung Screening Trial Research Team, 2011a). In 
addition, medical records were abstracted for complications related to diagnostic 
evaluation follow-up in those with positive screening tests, and in those diagnosed with 
lung cancer (National Lung Screening Trial Research Team, 2011a). Pathology and 
tumour-staging reports, records of operative procedures and initial treatments were 
recorded for participants diagnosed with lung cancer (National Lung Screening Trial 
Research Team, 2011a). In order to ensure that any lung cancers were not the result of 
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pulmonary metastasis from a non-pulmonary primary tumour, pathology reports were 
obtained for any non-lung cancer diagnoses (National Lung Screening Trial Research 
Team, 2011a). Histology and disease stage were determined by using the International 
Classification of Diseases for Oncology, 3rd edition (ICD-O-3), and the sixth edition of 
the Cancer Staging Manual of the American Joint Committee on Cancer (AJCC) 
(National Lung Screening Trial Research Team, 2011a). 
 To ensure data quality and accuracy, site audits were conducted regularly, image 
and screening equipment quality assurance programs were implemented, data accuracy 
and completeness checks were implemented in data collection, and standardized data 
collection procedures were used (National Lung Screening Trial Research Team, 2011b). 
Radiologist interpreting LDCT and CXR images were required to meet specific protocol 
requirements and were certified by appropriate boards or agencies, trained in image 
acquisition, and radiologists were additionally trained in image quality and standardized 
image interpretation (National Lung Screening Trial Research Team, 2011a). 
3.3 Associative Modeling and Survival Analysis 
 The following sections describe the approach taken to address the study aims of 
the proposed research. Topics include statistical methodology, variable selection, data 
preparation, assumptions checks, the model building approach, as well as the methods for 
evaluating and validating models. 
3.3.1 Sample Data 
 The source data used in the current research has been described in previous 
sections. A specific subsample of the source data was used for the purposes of this 
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research. Study aims 1 and 2 use a case-case study design nested in the NLST study. 
Small aggressive non-small cell lung carcinomas were considered case positive (C+), 
while large non-aggressive cancers (referred to as “controls”) were considered case 
negative (C-). SA-NSCLC cases have been previously described by Tammemägi et al. as 
lung cancer patients with T1 (<30 mm, minimal invasion of surrounding tissues) tumours, 
that have spread to distant regional lymph nodes (N3) or metastasized (M1), or both 
(Tammemägi et al., 2007). Non-SA-NSCLC cases (C-) were defined as tumours that have 
grown beyond T1 and will exclude individuals with locally aggressive disease (T4), 
distant nodal disease (N3), or metastases (M1), resulting in the primary control group 
containing patients with tumours that are T2 to T3, N0 to N2, and M0 (Tammemägi et al., 
2007). Clinically or pathologically ascertained tumour size measures were used to 
categorize tumours based on size (<30 mm versus ≥30 mm). 
Study aim 3 compared survivorship between stage IV SA-NSCLC and other stage 
IV non-SA-NSCLC. Cases (C+), as determined for the primary objective, were restricted 
to only stage IV cancers for the purposes of comparing post-diagnosis survival times. The 
primary control group for study aim 3 was stage IV NSCLC that were ≥30 mm in size. 
Survivorship was defined as the time from lung cancer diagnosis to the end-point of death, 
censoring, or study termination.  
3.3.2 Statistical Approach 
Two statistical approaches were employed to address the three study aims. Data 
preparation, analysis, model building, assumptions checks, and model evaluation and 
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validation were performed using Stata 13 statistical software (StataCorp. 2013. Stata 
Statistical Software: Release 13. College Station, TX: StataCorp LP). 
3.3.2.1 Study Aims 1 & 2 
The objective of study aims 1 & 2 was to characterize, identify, and validate 
factors related to SA-NSCLC. The outcome for this objective was a dichotomous variable 
(C+/C-), and thus logistic regression was the appropriate method to identify associations 
and compare results with previous research that employed similar techniques. Both 
univariate and multivariable logistic regression models were created using the statistical 
approach described in the following sections. 
3.3.2.2 Study Aim 3 
 The third aim of this study used both a dichotomous variable containing death due 
to lung cancer, in conjunction with survival time-to-event data. The dichotomous 
outcome variable represents death due to lung cancer (yes or no). Time-to-event data 
follows from lung cancer diagnosis to the endpoint of death, loss-to-follow up, or study 
termination. These variables were used to compare survivorship between groups, and Cox 
Proportional Hazards models were appropriate for these data. Kaplan-Meier survival 
function estimators were used for categorical covariates to graphically assess differences 
in survival functions across covariate strata, and log-rank tests were used to assess 
statistically significant differences in survival functions. Actuarial life-tables were used to 
assess overall and stratified survival and failure probabilities, and hazard rates over fixed 
time intervals for the purposes of comparing with literature estimates. 
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3.3.3 Candidate Predictors 
 For study aims 1 & 2, candidate predictors were chosen based on previously 
identified risk factors of SA-NSCLC, as well as based on literature and knowledge of 
lung carcinogenesis. Risk factors identified previously in multivariable analysis that were 
attempted to be validated in the current study include: Younger age at diagnosis, female 
sex, family history of lung cancer, and the interaction sex*family history of lung cancer. 
Younger age at diagnosis was previously used as a dichotomized variable (<65 versus 
≥65), but was first assessed as continuous. Risk factors that demonstrated possible 
association with SA-NSCLC in univariate analysis included: smoking duration, history of 
heart disease/infarction, and histology (adenocarcinoma versus other NSCLC). The 
previously identified inverse association of ibuprofen use could not be assessed due to 
absence of data. 
 In addition to validating previously identified factors, this study worked to 
elucidate novel factors of SA-NSCLC. Identifying candidate predictors was done using a 
priori knowledge of lung carcinogenesis, as well as through investigation of sensible 
predictors available in the dataset. Predictors that showed promise in univariate analysis, 
either by approaching statistical significance (P<0.15), or having effect estimates tending 
away from the null value, were evaluated further in multivariable models. Predictor 
variables that were evaluated for associations with SA-NSCLC are listed in Table 5. 
A similar approach was used to identify candidate predictors for study aim 3. 
Additionally, variables known or suspected to be associated with survival, such as age, 
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sex, smoking status, and others, were considered in models for the third study aim. Data 
on patient treatment strategies were not available.  
Table 5. Variables evaluated for associations with SA-NSCLC 
Category of variable Specific variables 
Sociodemographic (n=5) Age at diagnosis 
Sex 
Race/ethnicity 
Marital status 
Education 
Smoking exposures (n=5) Smoking status as former, current 
Pack years smoked 
Smoking duration (years) 
Smoking intensity (cigarettes smoker per day) 
Pipe/cigar smoking 
Medical history (n=19) Family history of lung cancer; personal 
history of cancer; body mass index 
Comorbidities: adult asthma, asbestosis, 
bronchiectasis, childhood asthma, chronic 
bronchitis, COPD, diabetes, emphysema, 
pulmonary fibrosis, heart attack/heart disease, 
hypertension, pneumonia, sarcoidosis, 
silicosis, stroke, and tuberculosis 
Index cancer related (n=2) Histology 
Grade 
Screening related (n=1) Randomization arm 
Interaction terms (n=4) Age*sex, age*FHxLCA, sex*FHxLCA, 
FHxLCA*smoking 
Abbreviations: COPD, chronic obstructive pulmonary disease; FHxLCA, family history of lung cancer. 
3.3.4 Data Preparation 
 Prior to model building, standard data cleaning and preparation methods were 
employed. All candidate predictor variables were evaluated for missing data, potential 
outliers, and biologically implausible values. Regarding missing data, multiple 
imputations were considered if missing data exceeded a 10% threshold for any variable, 
or in cases of missing data beyond 10%, variables were considered to be dropped from 
models, due to the effect it may have on model fit (Royston, Moons, Altman, & 
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Vergouwe, 2009; Sterne et al., 2009). Missing data was minimal for candidate predictors, 
and as such techniques for imputing data were not used in the current study.  
3.3.5 Descriptive Statistics 
For the purposes of comparing the samples used for the different aims of this 
study, descriptive statistics of the sample data were determined to both characterize the 
samples and identify differences and similarities between the groups. Categorization and 
collapsing of covariate levels was done minimally so as to avoid losing valuable 
information when model building, and was guided by knowledge of the topic and 
literature where available. Categorization and collapsing was done for descriptive 
purposes. Means and standard deviations were calculated for continuous covariates, and 
Student’s independent sample t-tests used to identify statistically significant differences 
in means between groups for variables that assumed normal distributions, and Wilcoxon 
rank-sum tests to compare populations for non-normal continuous covariates. Multi-level 
categorical covariates were assessed for differences in distributions using Pearson’s chi-
squared (χ2) tests of independence, or Fisher’s exact test where cell counts were small. 
3.3.6 Model Building Approach 
3.3.6.1 Handling Continuous Predictors 
 Continuous predictors that were considered for final models were not categorized 
so as to avoid losing information unnecessarily (Moons et al., 2012). Categorization was 
only be done where absolutely necessary, and guided by knowledge and literature. 
Potential non-linear relationships between continuous predictors and outcome variables 
were evaluated using multivariable fractional polynomials (MFP), which has been shown 
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to be more flexible in identifying non-linear effects when compared with some competing 
methods (Royston, Sauerbrei, & Amber, 1999). The default set of fractional polynomial 
(FP) powers used was -2, -1, -0.5, 0 (log), 0.5, 1, 2, and 3. In situations where multi-level 
ordinal variables were considered in models, they were assessed for possible pseudo-
continuity by evaluating trends in effect sizes when treated as indicator variables, and 
where possible, were treated as continuous to save degrees of freedom in logistic and Cox 
models. 
3.3.6.2 Evaluating Collinearity 
 A number of approaches were used in order to assess potential collinearity of both 
continuous and categorical covariates within the sample data. Primary investigation of 
collinearity amongst candidate continuous predictors was assessed using correlation 
matrices. In addition, Variance Inflation Factors (VIF) and tolerance values (1/VIF) were 
used to assess the degree of multi-collinearity amongst all candidate predictor variables, 
by using Stata’s estat vif command. Variance inflation factors indicate the factor by 
which the variance of a given predictor is inflated due to the lack of independence with 
all other predictor variables. A rule of thumb value for VIF’s of 10, and thus a tolerance 
threshold of 0.10, have been offered as thresholds for severe levels of collinearity 
(O’Brien, 2007). Suspected collinearity of categorical covariates was further assessed 
using McNemar’s test for paired data. Any predictor variables that demonstrated strong 
levels of collinearity were evaluated further. Methods for handling collinearity included 
combing variables to generate a unified predictor, transforming non-linear covariates, 
centering continuous covariates, or removal of one of the two collinear predictors from 
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the models. More complex methods of dealing with collinearity were avoided as they 
have been shown to cause more problems than they solve (O’Brien, 2007). 
3.3.6.3 Variable Selection 
 Identification of candidate predictors has been described previously; this section 
describes the protocol for including variables in the final models. Certain variables were 
evaluated in the multivariable models irrespective of promise in univariate models based 
on a priori reasoning. These variables include smoking duration and intensity, family 
history of lung cancer, and histology. All sensible two-way interactions of main effect 
variables were evaluated using likelihood-ratio tests (LRT) to assess significance of 
interaction terms. Type I (α) error was set at 0.05 for non-interactive main effects, and all 
P-values were reported as two-sided. Significance levels for interaction terms were 
loosened due to fragmenting cell counts in order to boost statistical power – statistical 
significance was P-values less than 0.10.  
 Due to relatively small sample sizes available for the study aims, predictor 
variable inclusion in final multivariable models were restricted to those for which data 
were present for at least 95% of SA-NSCLC and missing data did not differ significantly 
by SA-NSCLC/non-SA-NSCLC status. Final models were constructed, and variables 
included, based on reaching statistical significance in LRT for main effects and/or 
interaction terms, or forced into models based on prior knowledge of their predictive 
value. Individual variable significance in multivariable models was determined by using 
LRT comparing nested models (without the candidate predictor being tested) to the full 
model.  
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3.3.6.4 Assumption Checking 
3.3.6.4.1 Study Aims 1 & 2 
 For study aims 1 & 2 the assumptions of additivity of predictors in the log scale, 
and correct specification of the model, were addressed by checking for interaction and 
non-linearity, and by using Stata’s linktest command. In addition, good model building 
practices described previously worked to ensure no inclusion of extraneous variables, and 
the inclusion of all relevant variables available for analysis. 
3.3.6.4.2 Study Aim 3 
For the third study aim, one assumption that needed to be satisfied to ensure the 
Cox models have been fitted adequately is the Proportional Hazards (PH) assumption – 
which states that the survival curves for two strata must have hazard functions that 
remain proportional over time (Ng’andu, 1997). Numerous methods have been proposed 
for assessing the proportional hazards assumption, however, in this study Stata’s estat 
phtest command was utilized after fitting Cox models for this purpose (Ng’andu, 1997). 
This command uses Schoenfeld residuals to statistically assess the PH assumption, as 
well as plot the residuals as a function of time along with a locally weight scatterplot 
smoothing curve (LOWESS) to assess a non-zero slope (Grambsch & Therneau, 1994; 
Ng’andu, 1997). A non-significant p-value (P>0.05) indicated lack of evidence to reject 
the proportionality assumption. Log-log survival plots were used to graphically assess 
possible violations of the PH assumption for nominal or ordinal predictor variables. 
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3.4 Model Evaluation 
3.4.1 Internal Validation - Bootstrapping 
 By choosing to internally validate the models in this study no data was set aside to 
separately develop and validate models, as this is found to be statistically inefficient 
(Moons et al., 2012). The full available sample size was used for internal validation. In 
order to internally validate the results generated in this study bootstrapping techniques 
were employed. Bootstrapping involves repeated random sampling of the full sample 
with replacement to generate new bootstrap samples (Moons et al., 2012). These 
bootstrap samples are then used to estimate a given statistic or model to measure 
optimism or ensure stability of estimates (Moons et al., 2012). In order to validate 
significant associations found in final models, bootstrapping of models was done to 
assess stability of p-values and confidence intervals. Bootstrapping procedures generated 
new samples from which re-estimate final model parameters. Due to the random nature of 
the bootstrapping process, a random-number seed was chosen to ensure reproducibility of 
results. To ensure convergence of the bootstrapping process a large number of 
replications (reps = 2000) were chosen to generate stable bootstrap estimates. 
3.4.2 Fit Diagnostics 
 Fit diagnostic statistics were used to assess overall model fit, testing the null 
hypothesis that the model was fit correctly. The Hosmer-Lemeshow Goodness-of-Fit 
(GOF) test was used to test this hypothesis. The Hosmer-Lemeshow GOF test creates 10 
groups (deciles) based on fitted probabilities from a logistic regression model (Hosmer & 
Lemeshow, 2000). Observed versus expected event rates were compared across the decile 
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subgroups (Hosmer & Lemeshow, 2000). A non-significant p-value (P>0.05) indicates 
acceptable agreement between the observed and expected rates and that the model 
adequately fits the data (Hosmer & Lemeshow, 2000). 
3.4.3 Influential Observations 
Influential observations were investigated using a number of methods in order to 
assess observations that may have had a significant effect on models. Investigation of 
influential observations served an important purpose, to identify possible data entry errors, 
but also influential observations may be useful to study by themselves as aberrant cases, 
and may potentially skew effect estimates. Given the relatively small sample size of this 
study, observations had an increased possibility of exerting influence on model estimates. 
 Pearson standardized residuals and deviance residuals were used to evaluate 
observation influence. Pearson residuals are defined as the standardized differences 
between the observed and predicted frequency (Hosmer & Lemeshow, 2000). Deviance 
residuals are defined as the measure of disagreement between the maxima of the observed 
and fitted log-likelihood functions (Hosmer & Lemeshow, 2000). Following fitting of 
logistic regression models, predicted probabilities were calculated for each participant 
using their individual covariate pattern. The link function of a logistic regression model is 
the logit (log[x/1-x]), which can be evaluated to derive probabilities by taking the 
exponent of the logit function (exp x/1+exp x) after estimating the logit coefficient for 
each covariate pattern. Graphs were generated for predicted probabilities versus Pearson 
standardized residuals, and predicted probabilities versus deviance residuals. Overly 
influential observations were assessed and handled as necessary. 
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CHAPTER IV – RESULTS 
4.1 Population Demographics & Clinical Characteristics 
4.1.1 Primary Sample – Study Aims 1 & 2 
 Of the 2,058 lung cancers diagnosed in the NLST, 280 were identified as the 
primary sample to address study aims 1 and 2. The criteria for being included in the 
primary sample have been described in previous chapters. Using a case-case study design, 
60 SA-NSCLCs were identified as the case+ group, while 220 large non-aggressive 
NSCLCs were identified as the primary control group (case-). Tumour-Node-Metastasis 
(TNM) distribution for the primary sample is described in Table 6. At 53%, the majority 
of large non-aggressive lung cancers were T2N0M0 diagnosis, and overall ~88% were 
T2M0 tumours. The majority of SA-NSCLCs were metastatic (M1) (approx. 83%), while 
only approximately 17% of cancers were diagnosed as non-metastatic tumours with 
distant nodal spread (T1N3M0). 
Population demographics and clinical characteristics were similar across the two 
groups and can be seen in Table 7. The average age of lung cancer diagnosis was 66.0 
years (SD=5.0) for cases and 66.7 years (SD=5.9) for controls. Smoking histories 
(intensity, duration, and smoking status) were similar across both groups. Fisher’s exact 
tests identified differences in distributions for histology (P = 0.001), randomization group 
(P = 0.02), and race/ethnicity (P = 0.04) between cases and controls. In comparing 
adenocarcinomas (including bronchioloalveolar carcinomas) to other NSCLCs (squamous 
cell, large cell, and other), logistic regression analysis identified a significant univariate 
association with SA-NSCLC (OR=5.25; 95% CI: 2.59-10.63). Due to this result, along 
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with research that previously identified an association of SA-NSCLC with 
adenocarcinomas, subset analysis was performed on adenocarcinomas in order to identify 
possible histology specific associations (Tammemägi et al., 2007). 
Table 6. Tumour-Node-Metastases distribution amongst SA-NSCLC (n=60) 
(light grey) and large non-aggressive NSCLC (n=220) (dark grey). 
  NX N0 N1 N2 N3 
M0 T1     10 (17%) 
 T2  116 (53%) 32 (15%) 45 (20%)  
 T3  15 (7%) 2 (<1%) 10 (5%)  
M1 T1 1 (2%) 12 (20%) 6 (10%) 16 (27%) 15 (25%) 
*Percentages represent relative proportions separately amongst cases and controls 
4.1.2 Adenocarcinoma/BAC Subset 
 As described in the previous section, adenocarcinomas, including 
bronchioloalveolar carcinomas, were found to be strongly associated with SA-NSCLC. 
For the purposes of addressing study aims 1 & 2, a subset sample restricted to only 
adenocarcinomas was created in order to identify any histology specific associations. 
Similar to the primary sample, population demographics and clinical characteristics 
remained similar across cases and controls (Table 8). Differences in distributions were 
identified using Fisher’s exact test for previous diagnosis of emphysema (P = 0.01) and 
sex by family history of lung cancer interaction (P = 0.02). In univariate logistic 
regression analysis previous diagnosis of emphysema has a significant association 
(OR=5.05; 95% CI: 1.62-15.76). Contingency table analysis demonstrated females with a 
positive family history of lung cancer were associated with SA-NSCLC compared to 
males with no family history (OR=3.76; 95% CI: 0.98-15.82).
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Table 7. Demographic and clinical characteristics of the primary sample for study aims 1 & 2 (N = 280). Odds ratios, 95% confidence 
intervals, and P-values from univariate logistic regressions analysis. 
Variable 
Case +           
n = 60 (21%) 
Case -            
n = 220 (79%) 
P 
Median 
(25th/75th) 
Min/ 
Max 
OR (95% CI; P) 
SOCIODEMOGRAPHIC       
Age at diagnosis (y, mean [SD]) 66.0 [5.0] 66.7 [5.9] Ptt = 0.37 
66.0 
(62.5/70.6) 
55.1/ 
80.1 
OR(per 1 y) = 0.98 (0.93-1.03; P = 0.37) 
Sex       
         Female 24 (40%) 64 (29%)    OR(female vs. male) = 1.63 
(0.90-2.94; P = 0.11)          Male 36 (60%) 156 (71%) Pe = 0.12   
Race/ethnicity       
         White 59 (98%) 197 (90%)    OR(white vs. non-white) = 6.89  
(0.91-52.1; P = 0.06)          Non-White 1 (2%) 23 (10%) Pe = 0.04   
Education level       
         HS or less (low) 21 (36%) 84 (38%)    OR(high vs. low) = 1.12  
(0.61-2.03; P = 0.72)          More than HS (high) 38 (64%) 136 (62%) Pe = 0.76   
MEDICAL HISTORY       
Body mass index (kg/m2, mean [SD]) 26.8 [3.6] 27.1 [4.3] Ptt = 0.62 
26.4 
(24.4/29.2) 
16.9/ 
43.9 
OR(per 1 unit) = 0.98 (0.91-1.05; P = 0.62) 
Family history of LC       
         No 40 (68%) 155 (71%)    OR(yes vs. no) = 1.17  
(0.63-2.17; P = 0.62)          Yes 19 (32%) 63 (29%) Pe = 0.63   
Male, no FHxLC 26 (44%) 108 (50%)    
OR(Female, FHxLC vs. Male, No FHxLC) = 2.60  
(0.93-6.89; Pe = 0.04) 
Male, FHxLC 9 (15%) 47 (22%)    
Female, no FHxLC 14 (24%) 47 (22%)    
Female, FHxLC 10 (17%) 16 (7%) Pe = 0.14   
Emphysema       
         No 48 (81%) 198 (90%)    OR(yes vs. no) = 2.06  
(0.94-4.54; P = 0.07)          Yes 11 (19%) 22 (10%) Pe = 0.07   
COPD       
         No 46 (77%) 169 (77%)    OR(yes vs. no) = 1.01  
(0.51-1.98; P = 0.98)          Yes 14 (23%) 51 (23%) Pe = 0.99   
(Continued on the following page) 
 7
1
 
Variable 
Case +           
n = 60 (21%) 
Case -            
n = 220 (79%) 
P 
Median 
(25th/75th) 
Min/ 
Max 
OR (95% CI; P) 
Chronic bronchitis       
         No 52 (88%) 195 (89%)    OR(yes vs. no) = 1.05 
(0.43-2.56; P = 0.92)          Yes 7 (12%) 25 (11%) Pe = 0.99   
EXPOSURES       
Cigarettes / day (mean [SD]) 31.1 [13.7] 30.4 [12.5] Ptt = 0.74 30 (20/40) 12/90 OR(per 1 cig.) = 1.00 (0.98-1.03; P = 0.74) 
Years smoked (mean [SD]) 44.3 [7.2] 44.7 [7.1] Ptt = 0.69 44 (40/50) 29/67 OR(per 1 y) = 0.99 (0.95-1.03; P = 0.69) 
Pack-years (mean [SD]) 68.2 [29.1] 67.8 [30.8] Ptt = 0.93 63 (45/82) 30/232 OR(per 1 py) = 1.00 (0.99-1.01; P = 0.93) 
Smoking status       
         Current 38 (63%) 137 (62%)    OR(current vs. former) = 1.05  
(0.58-1.89; P = 0.88)          Former 22 (37%) 83 (38%) Pe = 0.99   
CANCER RELATED       
Tumour size (mm, mean [SD]) 18.2 [5.6] 47.1 [16.0] Ptt = 0.0001 40 (30/50) 8/115  
Histology       
         Adenocarcinoma 47 (78%) 94 (43%)    
OR(adeno/BAC. vs. other) = 5.25  
(2.59-10.63; P = 0.001) 
         Bronchioloalveolar carcinoma 2 (3%) 7 (3%)    
         Squamous cell carcinoma 8 (13%) 100 (45%)    
         Large cell carcinoma 2 (3%) 14 (6%)    
         Other NSCLC 1 (2%) 5 (2%) Pe = 0.001   
SCREENING RELATED       
Randomization group       
         CT 16 (27%) 97 (44%)    OR(CT vs. CXR) = 0.46  
(0.25-0.87; P = 0.02)          CXR 44 (73%) 123 (56%) Pe = 0.02   
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FHxLC, family history of lung cancer; HS, high school; LC, lung cancer; 
OR, Odds Ratio; Pe, p-value from Fisher’s Exact test; Ptt, p-value from t-test; SD, standard deviation; yrs, years.  
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Table 8. Descriptive and clinical characteristics of adenocarcinoma subset sample (n = 150). Odds ratios, 95% confidence intervals, and 
P-values from univariate logistic regressions analysis. 
Variable 
Case +           
n = 49 (33%) 
Case -            
n = 101 (67%) 
P 
Median 
(25th/75th) 
Min/ 
Max 
OR (95% CI; P) 
SOCIODEMOGRAPHIC       
Age at diagnosis (y, mean [SD]) 66.5 [5.2] 66.6 [5.7] Ptt = 0.89 
66.0 
(62.7/70.4) 
56.0/ 
79.4 
OR(per 1 y) = 1.00 (0.94-1.06; P = 0.89) 
Sex       
         Female 19 (39%) 34 (34%)    OR(female vs. male) = 1.25 
(0.62-2.53; P = 0.54)          Male 30 (61%) 66 (66%) Pe = 0.59   
Race/ethnicity       
         White 48 (98%) 93 (92%)    OR(white vs. non-white) = 4.13  
(0.50-34.0; P = 0.19)          Non-White 1 (2%) 8 (8%) Pe = 0.27   
Education level       
         HS or less (low) 17 (35%) 31 (31%)    OR(high vs. low) = 0.81  
(0.39-1.67; P = 0.57)          More than HS (high) 31 (65%) 70 (69%) Pe = 0.58   
MEDICAL HISTORY       
Body mass index (kg/m2, mean [SD]) 26.4 [3.2] 27.3 [4.4] Ptt = 0.17 
26.6 
(24.4/29.4) 
16.9/ 
43.9 
OR(per 1 unit) = 0.94 (0.86-1.03; P = 0.17) 
Family history of LC       
         No 32 (67%) 74 (74%)    OR(yes vs. no) = 1.42  
(0.67-3.01; P = 0.36)          Yes 16 (33%) 26 (26%) Pe = 0.44   
Male, no FHxLC 22 (46%) 46 (46%)    
OR(Female, FHxLC vs. Male, no FHxLC) = 3.76 
(0.98-15.82; Pe = 0.03) 
Male, FHxLC 7 (15%) 21 (21%)    
Female, no FHxLC 10 (21%) 28 (28%)    
Female, FHxLC 9 (19%) 5 (5%) Pe = 0.06   
Emphysema       
         No 38 (79%) 96 (95%)    OR(yes vs. no) = 5.05  
(1.62-15.76; P = 0.01)          Yes 10 (21%) 5 (5%) Pe = 0.01   
COPD       
         No 35 (73%) 81 (80%)    OR(yes vs. no) = 1.46  
(0.66-3.26; P = 0.35)          Yes 13 (27%) 20 (20%) Pe = 0.40   
(Continued on the following page) 
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Variable 
Case +           
n = 60 (21%) 
Case -            
n = 220 (79%) 
P 
Median 
(25th/75th) 
Min/ 
Max 
OR (95% CI; P) 
Chronic bronchitis       
         No 41 (85%) 87 (86%)    OR(yes vs. no) = 1.06 
(0.40-2.83; P = 0.91)          Yes 7 (15%) 14 (14%) Pe = 0.99   
EXPOSURES       
Cigarettes / day (mean [SD]) 30.7 [14.2] 30.9 [13.3] Ptt = 0.93 30 (20/40) 12/90 OR(per 1 cig.) = 1.00 (0.97-1.02; P = 0.93) 
Years smoked (mean [SD]) 45.1 [7.2] 43.6 [6.7] Ptt = 0.23 43 (39/49) 30/59 OR(per 1 y) = 1.03 (0.98-1.08; P = 0.23) 
Pack-years (mean [SD]) 68.2 [29.2] 67.4 [32.8] Ptt = 0.88 
62.5 
(44/80) 
32/232 
OR(per 1 py) = 1.00 (0.99-1.01; P = 0.88) 
Smoking status       
         Current 31 (63%) 55 (54%)    OR(current vs. former) = 1.44  
(0.71-2.90; P = 0.31)          Former 18 (37%) 46 (46%) Pe = 0.38   
CANCER RELATED       
Tumour size (mm, mean [SD]) 18.4 [5.8] 44.6 [14.5] Ptt = 0.0001 35 (24/45) 8/115  
SCREENING RELATED       
Randomization group       
         CT 15 (31%) 42 (42%)    OR(CT vs. CXR) = 0.62  
(0.30-0.1.28; P = 0.20)          CXR 34 (69%) 59 (58%) Pe = 0.21   
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FHxLC, family history of lung cancer; HS, high school; LC, lung cancer; 
OR, Odds Ratio; Pe, p-value from Fisher’s Exact test; Ptt, p-value from t-test; SD, standard deviation; y, years. 
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Table 9. Descriptive and clinical characteristics of the primary sample (stage IV NSCLCs) for study aim 3 (n=210). Hazard ratios (HR), 
95% CIs, and P-values from univariate Cox Proportional Hazards models. 
Variable 
Stage IV-
SA-NSCLC 
n = 50 (24%) 
Stage IV-
Large             
n = 160 (76%) 
P 
Median 
(25th/75th) 
Min/ 
Max 
 HR (95% CI; P) 
SOCIODEMOGRAPHIC       
Age at LC diagnosis (y, mean [SD]) 65.5 [4.6] 67.3 [5.3] Ptt = 0.04 
66.5 
(63.0/71.0) 
55.7/ 
81.1 
HR(per 1 y) =  1.00 (0.97-1.03; P = 0.91) 
Sex       
         Male 29 (58%) 107 (67%)    HR(female vs male) = 1.03 
(0.75-1.41; P = 0.85)          Female 21 (42%) 53 (33%) Pe = 0.31   
Race/ethnicity       
          White 49 (98%) 144 (90%)    HR(white vs non-white) = 0.79  
(0.46-1.34; P = 0.37)           Non-White 1 (2%) 16 (10%) Pe = 0.08   
Education level       
          HS or less (low) 17 (35%) 69 (44%)    HR(high vs low) = 1.09  
(0.80-1.48; P = 0.59)           More than HS (high) 32 (65%) 88 (56%) Pe = 0.32   
MEDICAL HISTORY       
Body mass index (kg/m2, mean [SD]) 26.8 [3.7] 26.7 [4.5] Ptt = 0.85 
26.1 
(23.8/29.2) 
18.3/ 
46.6 
HR(per 1 unit) = 0.97 (0.94-1.00; P = 0.08) 
Emphysema       
         No 41 (84%) 138 (88%)    HR(yes vs no) = 0.55  
(0.35-0.88; P = 0.01)          Yes 8 (16%) 20 (12%) Pe = 0.48   
COPD       
         No 39 (78%) 122 (76%)    HR(yes vs no) = 0.77  
(0.54-1.09; P = 0.14)         Yes 11 (22%) 38 (24%) Pe = 0.85   
Chronic bronchitis       
         No 44 (90%) 142 (90%)    HR(yes vs no) = 0.99  
(0.60-1.63; P = 0.96)          Yes 5 (10%) 16 (10%) Pe = 0.99   
EXPOSURES       
Cigarettes / day (mean [SD]) 31.6 [13.7] 30.4 [12.5] Ptt = 0.57 30 (20/40) 15/100 HR(per 1 cig.) = 0.99 (0.97-1.00; P = 0.04) 
Years smoked (mean [SD]) 43.9 [6.9] 43.7 [7.1] Ptt = 0.84 
44.5 
(40/48) 
20/59 
HR(per 1 y) = 0.99 (0.97-1.02; P = 0.55) 
Pack-years (mean [SD]) 69.0 [28.6] 65.4 [26.3] Ptt = 0.42 
58.5 
(46/84) 
30/177 
HR(per 1 py) = 0.99 (0.99-1.00; P = 0.03) 
(Continued on the following page) 
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Variable 
Stage IV-
SA-NSCLC 
n = 50 (24%) 
Stage IV-
Large             
n = 160 (76%) 
P 
Median 
(25th/75th) 
Min/ 
Max 
 HR (95% CI; P) 
Smoking status       
          Current 33 (66%) 84 (53%)    HR(current vs former) = 0.90  
(0.67-1.22; P = 0.51)           Former 17 (34%) 76 (47%) Pe = 0.11   
CANCER RELATED       
Tumour size (mm, mean [SD]) 18.6 [5.4] 51.6 [18.5] Ptt = 0.0001 40 (30/57) 9/130 HR(per 1 mm) = 1.02 (1.01-1.02; P=0.001) 
Survival (y, median) 0.70 0.50  
0.55 
(0.25/0.99) 
0.01/ 
6.7 
 
Histology       
          Adenocarcinoma 38 (76%) 96 (60%)    
HR(adeno/BAC vs other) = 1.11  
(0.80-1.53; P = 0.54) 
          Bronchioloalveolar carcinoma 2 (4%) 2 (1%)    
          Squamous cell carcinoma 8 (16%) 50 (31%)    
          Large cell carcinoma 2 (4%) 6 (4%)    
          Other NSCLC 0 (0%) 6 (4%) Pe = 0.06   
SCREENING RELATED       
Randomization group       
         CXR 37 (74%) 97 (61%)    HR(CT vs CXR) = 1.06 
(0.77-1.45; P = 0.74)          CT 13 (26%) 63 (39%) Pe = 0.09   
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HS, high school; LC, lung cancer; OR, Odds Ratio; Pe, p-value from 
Fisher’s Exact test; Ptt, p-value from t-test; SD, standard deviation; y, years. 
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4.1.3 Primary Sample - Study Aim 3 
 For the third study aim, SA-NSCLCs identified in the primary sample for study 
aims 1 and 2 were restricted to only stage IV lung cancers in order to compare 
survivorship (time from diagnosis of lung cancer to death/censorship) with large stage IV 
NSCLC. For this purpose, 50 stage IV SA-NSCLC and 160 large stage IV NSCLC were 
identified in this study sample. Population demographics and clinical characteristics were 
similar between the two groups and are described in Table 9. Mean age at diagnosis was 
different between the two groups (65.5 versus 67.3; P = 0.04). The median survival time 
was 0.70 years for the stage IV SA-NSCLC, and 0.50 years for large stage IV NSCLC. 
Overall median survival time for stage IV NSCLCs contained in the sample for study aim 
3 was 0.55 years. Differences in survivorship will be discussed in subsequent sections. 
4.2 Risk Factors Associated with SA-NSCLC – Study Aims 1 & 2 
 Initial model building began by creating multivariable adjusted models using the 
full primary sample. Subset analysis was performed due to the strong association of SA-
NSCLC with adenocarcinomas, in addition to notably modifying the effects of other 
candidate predictors when a dichotomous histology variable (adenocarcinoma versus 
other NSCLC) was included in multivariable models. The most important findings of the 
current research were identified in adenocarcinomas; the subsequent detailing of results 
for study aims 1 and 2 are focused on analysis performed using the adenocarcinoma 
subset. Final logistic regression models were created to identify multivariable adjusted 
associations of predictors with SA-NSCLC amongst adenocarcinomas (Table 10).  
A previous diagnosis of emphysema was found to have a significant association 
with SA-NSCLC (OR=5.57; 95% CI: 1.68-18.43; P = 0.005). The interaction of female 
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sex with a positive family history of lung cancer was found to have a significant 
multiplicative interactive association with SA-NSCLC (OR=8.48; 95% CI: 1.53-47.02; P 
= 0.01). This result agrees with previous research on SA-NSCLC that identified a similar 
sex by family history of lung cancer interaction (OR=7.39; 95% CI: 1.17-46.58) in a 
different population (Tammemägi et al., 2007). A likelihood ratio test (LRT) was used to 
compare the full model (with the interaction term) to the nested model (without the 
interaction term) to assess significance of the interaction term in the final logistic model. 
The full model had significantly better fit (LRT: P = 0.01). The interactive association 
between sex and family history of lung cancer is described in more detail in Table 11. 
Using adjusted effects estimates for sex (ORF vs. M=1.34) and for family history of lung 
cancer (ORYes vs. No=1.44), under a simple multiplicative model, the expected odds ratio 
for females with a family history of lung cancer would be 1.93 (1.34*1.44), however, the 
current research has identified a significant interactive effect with an odds ratio of 8.48. 
The previously identified association of SA-NSCLC with a younger age at diagnosis was 
tested as both a continuous and dichotomous (<65 versus ≥65) predictor, and was not 
validated in the current research. In addition, regular use of ibuprofen was found to have 
an inverse association with SA-NSCLC in previous research but could not be validated in 
the current research due to no available data on ibuprofen use in the current data set. 
 For SA-NSCLC in the primary sample, primary lung tumours ranged from 8 mm 
to 30 mm in long axis. In the NLST, there were 1,457 NSCLC, and 833 were less than 30 
mm in long axis. Of these 833 cancers, approximately 7% (60 of 833) were SA-NSCLC. 
Only 1 SA-NSCLC was 8 mm, and none were smaller. The smallest metastatic (M1) 
tumour was 9 mm. The majority (95%) of SA-NSCLC were at or beyond 10 mm. This 
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approximately 10 mm (1 cm) long axis measure may indicate a lower size boundary for 
lung tumours to become clinically aggressive while the primary tumour is relatively small, 
and in some circumstances become SA-NSCLC. A histogram of lesion size distribution 
for SA-NSCLC, stratified by NLST screening arm, is presented in supplemental material 
(Figure S1). Most SA-NSCLC, and all SA-NSCLC less than 10 mm, were detected in the 
CXR arm. The distribution of cases and controls by screening arm and histology are 
described in Table S2. Boundaries for tumour size and metastases are discussed in the 
following chapter. 
Table 10. Final and bootstrapped multivariable logistic regression models for 
predictors of SA-NSCLC among adenocarcinomas (n=148). 
 Final Model Bootstrapped Model* 
Variable OR (95% CI; P) 95% CI; P 
Emphysema diagnosis 5.57 (1.68-18.43; P=0.005) 1.26-24.68; P=0.02 
Sex (F vs. M) 0.79 (0.32-1.95; P=0.61) 0.31-2.03; P=0.63 
FHxLC 0.56 (0.19-1.62; P=0.28) 0.13-2.31; P=0.42 
Sex*FHxLC interaction 8.48 (1.53-47.02; P=0.01) 1.07-67.39; P=0.04 
LRT for Sex*FHxLC interaction P = 0.01 -- 
Abbreviations: CI, confidence interval; FHxLC, family history of lung cancer; LRT, likelihood ratio test;  
OR, odds ratio; P, p-value. 
* One or more parameters could not be estimated in 27/2000 bootstrap replicates (99% convergence) 
 
Table 11. Sex by family history of lung cancer 
interactive association with SA-NSCLC. Odds 
ratio (95% confidence interval). 
  
Sex 
 
 Male Female 
FHxLC 
No 1.0 (ref.) 
1.34  
(0.66-2.75) 
Yes 
1.44  
(0.68-3.04) 
8.48*  
(1.53-47.02) 
* Indicates statistical significant at P < 0.05 
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4.2.1 Model Evaluation 
 Internal validation techniques were used in order to ensure that the results 
generated in the final multivariable logistic model were not the result of an overly fit 
model to the primary sample. No data were set aside to separately train and validate the 
models; the final model was internally validated using the full available sample. 
Bootstrapping techniques were used - 2000 bootstrap replicate samples were generated to 
re-estimate the multivariable logistic regression models. Bootstrap p-values and 95% 
confidence intervals are displayed alongside the final model estimates in Table 10. Due to 
empty cells resulting from the resampling process, one or more of the logistic model 
parameters could not be estimated in some of the bootstrap replicate samples - 
convergence was achieved in 99% of bootstrap samples. The p-value for previous 
diagnosis of emphysema remained similar in the bootstrapped model compared to the 
final model (P = 0.005 versus P = 0.02). The sex by family history of lung cancer 
interaction term remained significant (P = 0.04). 
 Hosmer-Lemeshow goodness-of-fit tests were used to assess overall model fit. 
The final model contained only dichotomous predictors, and limited covariate patterns 
created ties at quantile probability boundaries. The Hosmer-Lemeshow decile table was 
collapsed to create 5 distinct quantiles. Overall the null hypothesis of model fit was not 
rejected (P = 0.85). In addition, a Pearson χ2 goodness-of-fit test was used to further 
assess model fit. The null hypothesis was not rejected (P = 0.54) indicating acceptable 
agreement between the observed and expected values, and that the model adequately fits 
the data. Results from goodness-of-fit tests can be found in Supplemental Material S3-S5. 
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4.3 Survival Analysis – Study Aim 3 
 Actuarial life-table estimates for stage IV lung cancer-specific mortality were 
generated for 1-year intervals. For each 1-year interval hazard rates, and survival and 
failure probabilities were estimated. Overall, for all stage IV lung cancers included in the 
sample used for study aim 3, the 1-, 2-, and 5-year survival probabilities were 29%, 18%, 
and 9%, respectively (Table 12). Life-tables were then stratified by tumour size (≥30 mm 
versus <30 mm). For large (≥30 mm) stage IV NSCLCs, 1-, 2-, and 5-year survival 
probabilities were 26%, 16%, and 5% respectively, while stage IV SA-NSCLCs had 1-, 
2-, and 5-year survivals of 41%, 23%, and 20%, respectively (Table 13). Overall survival 
was better for smaller tumours when compared with larger stage IV counterparts. A 
Kaplan-Meier (KM) stepwise plot of cumulative survival over time is shown in 
Supplemental Figure S6. Overall survival in stage IV cancers is poor. When stratified by 
tumour size (≥30 mm versus <30 mm), the KM plot indicates poorer survival for 
physically larger stage IV NSCLC. A log-rank test for equality of survival functions 
between large and small stage IV tumours found a significant difference (P = 0.03; 
Supplemental Table S7). Nelson-Aalen cumulative hazard functions for lung cancer-
specific mortality are shown in Supplemental Material S8-S9. The cumulative hazard 
function is steepest during approximately the first year following lung cancer diagnosis. 
This demonstrates the risk of dying from lung cancer is highest shortly after diagnosis. 
This agrees with the life-table hazard rates that are highest early on, and attenuate at later 
times. The slope of the cumulative hazard rate function is steeper for large stage IV lung 
cancers when compared to smaller stage IV lung cancers (Supplemental Figure S9). 
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Table 12. Actuarial life table estimates for lung cancer mortality among stage IV 
non-small cell lung carcinomas (n=210). 
    Interval 
Beg. 
Total 
Deaths Lost Survival Failure Hazard 
0 1 210 143 15 0.2938 0.7062 1.0916 
1 2 52 19 9 0.1763 0.8237 0.5000 
2 3 24 5 5 0.1353 0.8647 0.2632 
3 4 14 1 5 0.1235 0.8765 0.0909 
4 5 8 2 0 0.0926 0.9074 0.2857 
5 6 6 1 2 0.0741 0.9259 0.2222 
6 7 3 0 3 0.0741 0.9259 0.0000 
 
Table 13. Actuarial life table estimates for lung cancer mortality among stage IV 
non-small cell lung carcinomas stratified by tumour size (small vs large) (n=210). 
Interval 
Beg. 
Total 
Deaths Lost Survival Failure Hazard 
Large ( 30 mm)       
0 1 160 115 10 0.2581 0.7419 1.1795 
1 2 35 12 7 0.1598 0.8402 0.4706 
2 3 16 4 4 0.1141 0.8859 0.3333 
3 4 8 1 3 0.0966 0.9034 0.1667 
4 5 4 2 0 0.0483 0.9517 0.6667 
6 7 2 0 2 0.0483 0.9517 0.0000 
Small (< 30 mm)       
0 1 50 28 5 0.4105 0.5895 0.8358 
1 2 17 7 2 0.2309 0.7691 0.5600 
2 3 8 1 1 0.2001 0.7999 0.1429 
3 4 6 0 2 0.2001 0.7999 0.0000 
5 6 4 1 2 0.1334 0.8666 0.4000 
6 7 1 0 1 0.1334 0.8666 0.0000 
 
 Cox regression models for predictors of stage IV lung cancer-specific mortality 
are shown in Table 14. Smoking status, histology, and age at diagnosis were included in 
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multivariable Cox regression models based on prior knowledge of these factors as 
prognostic factors for lung cancer mortality (Tammemägi, Neslund-Dudas, Simoff, & 
Kvale, 2004). While these clinical features have been demonstrated to have an effect on 
overall lung cancer survival, their prognostic value amongst advanced stage non-small 
cell lung cancers are inconsistent (Abbasi & Badheeb, 2011; Maeda et al., 2000). 
Smoking status (current versus former) had no significant effect on survival amongst 
stage IV lung cancers (HR=1.02; 95% CI: 0.74-1.40). Both adeno-/bronchioloalveolar 
carcinomas (HR=0.75; 95% CI: 0.58-1.84), and squamous cell carcinomas (HR=0.58; 
95% CI: 0.39-1.39) had no significant effect on survival when compared to other NSCLC. 
Age at diagnosis had no significant effect on stage IV lung cancer survival (HR=1.00; 
95% CI: 0.97-1.03). Tumour size was found to have a significant effect on survival 
amongst individuals with stage IV cancer. Stage IV SA-NSCLCs were found to have a 
34% reduced hazard of lung-cancer mortality over the 7-year follow-up (HR=0.66; 95% 
CI: 0.45-0.96) when compared to large stage IV NSCLCs. Results remained independent 
of NLST randomization arm (CT versus CXR). Since few factors offer prognostic ability 
amongst stage IV lung cancers, multivariable model adjustment for lung cancer 
prognostic factors (smoking status, histology, and age at lung cancer diagnosis) offered 
no prognostic value. Univariate Cox regression analysis of the effect of tumour size on 
stage IV lung cancer mortality is displayed alongside the multivariable adjusted model in 
Table 14. The effect of tumour size (small versus large) on survival remained similar 
between the univariate and multivariable models. 
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Table 14. Univariate and multivariable Cox Proportional Hazards models for 
stage IV SA-NSCLC and large stage IV NSCLC as predictors of lung cancer 
mortality (n=210). 
Variable 
Hazard 
Ratio 
P 
95% Confidence 
Interval 
Univariate    
Stage IV SA-NSCLC (vs. Large Stage IV NSCLC) 0.67 0.03 0.46 – 0.96 
Multivariable    
Stage IV SA-NSCLC (vs. Large Stage IV NSCLC) 0.66 0.03 0.45 – 0.96 
Smoking status (vs. Former)    
     Current 1.02 0.91 0.74 – 1.40 
Histology (vs. other NSCLC)    
     Squamous cell 0.58 0.10 0.30 – 1.10 
     Adeno-/Bronchioloalveolar 0.75 0.34 0.41 – 1.36 
Age at diagnosis (years) 1.00 0.83 0.97 – 1.03 
Abbreviations: SA-NSCLC, small aggressive non-small cell lung carcinomas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Kaplan-Meier survival functions for stage IV SA-NSCLC and large stage IV 
NSCLC. Survival functions are significantly different (Log-rank test – P=0.03 – Table S7). 
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4.4 Proportional Hazards Assumption 
 A number of methods were used to test the proportional hazards assumption for 
Cox regression models used in addressing study aim 3. Log-log survival plots were used 
to graphically assess any non-parallel hazard functions for nominal or ordinal categorical 
predictors. Log-log survival plots for all categorical predictors included in the final Cox 
model can be found in supplemental material. Additionally, Schoenfeld residual plots 
were generated for all variables following fitting of the final adjusted Cox Proportional 
Hazards model. Schoenfeld residual plots were used for further graphical assessment of 
potential violations of the proportional hazard assumption. An example of a Schoenfeld 
residual plot for age is shown in Supplemental Figure S10. A zero-slope for the 
LOWESS curve of the residuals versus time indicates non-violation of the assumption of 
proportionality. Using Schoenfeld residuals, the proportional hazard assumption was 
tested statistically for each variable, as well as a global test for the overall model. The 
results of the proportional hazards test using Schoenfeld residuals are described in Table 
15. The hazard functions for some variables appeared to have potential non-parallel or 
crossing-over of functions (Supplemental Figures S11-S13); however, all variables 
included in the final model individually and collectively met the proportional hazard 
assumption using Schoenfeld residuals (p>0.05). 
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Table 15. Testing the proportional hazards assumption for Cox model (Table 14). 
Variable rho Χ2 P 
Stage IV SA-NSCLC (ref. large stage IV NSCLC) -0.01751 0.05 0.8188 
Smoking status (ref. Former)    
     Current -0.00954 0.02 0.8990 
Histology (ref. other NSCLC)    
     Squamous cell -0.07445 0.97 0.3249 
     Adeno-/Bronchioloalveolar 0.00086 0.00 0.9908 
Age at diagnosis 0.01262 0.03 0.8643 
Global Test  3.32 0.6515 
Abbreviations: SA-NSCLC, small aggressive non-small cell lung carcinomas; ref., reference group. 
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CHAPTER V – DISCUSSION 
5.1 Population Demographics & Clinical Characteristics 
The average age at diagnosis for lung cancer in the general U.S. population is 
around 70 years of age, and is higher than the average age of lung cancer diagnosis in the 
NLST of approximately 66 years (American Cancer Society, 2015d). For the primary 
sample identified for the current research, the average age at diagnosis was similar across 
both groups (66.0 and 66.7) and both values were similar to the NLST population. 
Participants enrolled in the NLST were selected to be racially/ethnically representative of 
high-risk U.S. population of smokers (National Cancer Institute, 2014a). Cases of SA-
NSCLC were found to be disproportionately white, when compared to large non-
aggressive NSCLC (controls). In the NLST, 90% of participants were non-Hispanic white, 
4% were non-Hispanic black, 1% were Hispanic, 2% were Asian, 1% were more than one 
race, and each of Native Hawaiian or Pacific Islander, and American Indian or Alaskan 
Native represented less than 1%. This differs significantly from the racial/ethnic 
distribution of U.S. population which is 63% white, 12% black or African American, 
17% Hispanic, 5% Asian, with all other races, including mixed races, making up the 
remaining 3% (United States Census Bureau, 2013). The NLST cohort has a distribution 
of sex and pack-years history of smoking similar to those who meet the major NLST 
criteria in the general U.S. population (Aberle et al., 2010). When compared with 
respondents to a 2002-2004 U.S. Census survey of tobacco use on those who met the 
NLST criteria for age and smoking history (described in previous sections), the NLST 
population were found to be younger, more educated, and more likely to be former 
smokers than the general population (National Lung Screening Trial Research Team, 
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2011a). While the NLST population is semi-representative of the general U.S. population 
who meet the major NLST criteria, less than 1% of the total NLST population was used 
in model building for the current research. For these reasons the results of the current 
study may not be generalizable to the U.S. population from which the data were 
ascertained, however, the suspected associations are believed to be biological in nature, 
and thus are expected to function similarly in the general population. 
Selection of the primary control group is important for epidemiological studies. 
The primary control group used to address study aims 1 and 2 included patients with 
tumours that are T2 to T3, N0 to N2, and M0. Non-aggressive T1 tumours were excluded 
from the control group so as to avoid potential misclassification as these tumours were 
considered to still have the potential to spread to distant lymph nodes and metastasize, 
and thus could be early stage SA-NSCLC. Similarly, large (>T1) aggressive tumours 
were excluded as they could have been SA-NSCLC that had the opportunity to grow in 
size and were identified later in disease course. As such, the control group only contains 
tumours that have not, and could not have, gone through SA-NSCLC disease course. 
5.2 Risk Factors for SA-NSCLC 
 In the current study, adenocarcinomas (including bronchioloalveolar carcinomas) 
were found to be significantly associated with SA-NSCLC. Adenocarcinomas have been 
previously found to be more aggressive when compared to other non-small cell histologic 
subtypes, with metastases occurring earlier in disease course (College of American 
Pathologists, 2011a; Collins et al., 2007). Adenocarcinomas remain disproportionately 
higher in females than males, despite being the most common lung cancer subtype for 
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both sexes. Previous research on SA-NSCLC found similar associations of 
adenocarcinomas with SA-NSCLC when compared to other NSCLC (Tammemägi et al., 
2007). Lung adenocarcinomas appear to be more likely to have distant metastases while 
the primary tumour remains relatively small in size when compared to other non-small 
cell cancers. The consistent relationship between adenocarcinomas and small aggressive 
lung cancers led to subset analysis of primary sample restricted to only adenocarcinomas. 
The purpose for subset analysis was to attempt to identify any possible histology specific 
risk factors for SA-NSCLC.  
One goal of the current study was to validate the previously identified sex by 
family history of lung cancer interaction (Tammemägi et al., 2007). The current research 
was able to validate this finding; females with a positive family history of lung cancer in 
a first-degree relative were at a much higher risk of having small aggressive lung cancer 
than large non-aggressive lung cancer. The interaction was only significant amongst 
adenocarcinomas. This result is particularly important, as it has now been validated in a 
similar but separate population, and provides evidence into the potential causal role of 
heritable factors interacting with female factors in the development of SA-NSCLC. The 
study findings suggest that heritable genetic factors may interact with female factors 
leading to early progression of lung cancer in some circumstances. The specific heritable 
factors remain to be identified, as well as what specific female factors may play a role. 
While it is not within the purview of the current research to identify the specific heritable 
gene(s) or gene mutations associated with SA-NSCLC, the following section will provide 
speculation on the potential role of certain genetic and non-genetic factors in the 
pathophysiology of these small aggressive cancers. 
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 Neuroendocrine differentiation (NED) is becoming a topic of growing interest in 
the field of lung cancer. NED in cancer is characterized by malignant tissue that contains 
a significant proportion of neuroendocrine cells that can secrete factors (hormones) that 
can stimulate and coordinate cancer growth (Grigore, Ben-Jacob, & Farach-Carson, 
2015). SCLCs are considered neuroendocrine tumours of the lung, however, recently the 
role of neuroendocrine factors in development, treatment, and prognosis of NSCLC has 
become of major interest (Howe et al., 2005; Rekhtman, 2010). Neuroendocrine secretion 
products such as serotonin, somatostatin, and bombesin have been identified as playing a 
possible role in growth, invasiveness, metastatic processes, and angiogenesis in prostate 
cancer (Hansson & Abrahamsson, 2001). Neuroendocrine cells can be identified by 
immunohistochemical staining or by electron microscopy of tissue specimen (Howe et al., 
2005). Neuroendocrine differentiation can be demonstrated in 10-30% of conventional 
NSCLC (Howe et al., 2005). Some studies have identified NED as being more common 
in adenocarcinomas when compared to other NSCLC, while others suggest no difference 
exists (Berendsen et al., 1989; Howe et al., 2005). Neuroendocrine differentiation may 
play an important role in the growth and metastatic potential in some non-small cell lung 
tumours. In a study by Howe et al. (2005), 36% of adenocarcinomas were found to have 
NED. Given the highly aggressive nature of SA-NSCLC, and the tendency to be 
adenocarcinomas compared to other histologic types, there is cause for speculation for a 
neuroendocrine role in the early progression of some of these tumours. 
 Adenocarcinomas represented the vast majority of SA-NSCLC in the current 
study (78%). The link between female factors, such as sex hormones, and heritable genes 
or gene mutations in causing lung cancer is not clear, but there is cause for speculation. A 
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number of somatic gene mutations have been identified as potentially playing a role in 
the development of lung cancer. Much less is known of inherited gene mutations. Two of 
the most common gene mutations in lung cancer encode for epidermal growth factor 
receptors and KRAS proteins (Greulich, 2010). KRAS gene mutations are the most 
frequently occurring mutated oncogenes in lung adenocarcinomas (Greulich, 2010). A 
single nucleotide polymorphism in the KRAS gene, known as the KRAS variant, has 
been identified as an inherited gene mutation that may play a role in cancer risk and 
altered tumour biology (Cerne, Stegel, Gersak, & Novakovic, 2012). The KRAS variant 
contains a germline single nucleotide polymorphism rs61764370 in the 3’-untranslated 
region of the KRAS oncogene (Cerne et al., 2012). Carriers of this gene variant tend to 
develop highly aggressive cancers. This gene variant has previously been associated with 
a 2.3-fold increase in the risk of NSCLC among moderate smokers (Cerne et al., 2012). 
The relationship between the KRAS variant and hormone replacement therapy in breast 
cancer has been described in the literature, and a similar relationship may exist in lung 
cancer (Cerne et al., 2012). Research by Cerne et al. (2012) has suggested possible 
interaction between the KRAS variant and steroid hormone exposure in hormone 
replacement therapy. This research indicates a potential interactive pathway between 
female sex hormones and inherited KRAS gene mutations in colorectal adenocarcinoma 
and breast cancer patients, a similar such model may exist in lung adenocarcinomas. 
5.2.1 Lung Comorbidities 
 In both univariate and multivariable analysis a previous diagnosis of emphysema 
was associated with SA-NSCLC. Lung comorbidities have been previously linked to an 
increased risk for developing lung cancer, however, results from the current study 
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implicate previous lung comorbidities such as emphysema as playing a role in early 
disease progression (Brenner et al., 2011). Chronic obstructive pulmonary diseases, such 
as emphysema, are pathologically characterized by activation of inflammatory processes 
of the lung (Sharafkhaneh, Hanania, & Kim, 2008). The proposed mechanisms by which 
an inflammatory response could contribute to carcinogenesis include through increased 
genetic mutations, anti-apoptotic signaling, and increased angiogenesis (Brenner et al., 
2011).  
Increased angiogenesis is considered a required precursor for tumour growth, and 
for tumour cells to enter the blood stream and metastasize (Folkman, 2002; Zetter, 1998). 
An imbalance between angiogenic and angiostatic factors can allow tumours to reach 
their metastatic potential (Folkman, 2002). Inflammation induced-angiogenesis may play 
an important role in the progression of lung tumours. Avascular tumours have limited 
capacity for growth and metastases (Folkman, 2002). Chronic lung inflammation 
associated with certain lung comorbidities may upregulate factors that promote 
angiogenesis. Inflammation can activate cell populations that release angiogenic factors 
including vascular endothelial growth factor (VEGF), platelet derived growth factor 
(PDGF), fibroblast growth factor (FGF), tumour necrosis factor (TNF-α), and adenosine 
(Granger & Senchenkova, 2010). Increased levels of these proangiogenic factors may 
allow for increased vascularization of tumours, increasing growth and metastatic potential 
(Folkman, 2002; Zetter, 1998). Results from the current study provide evidence 
implicating lung comorbidities, such as emphysema, in increasing the risk of early 
progression. Future research on the angiogenic profiles of these small aggressive cancers 
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may offer insight into the role of inflammation in carcinogenesis and early disease 
progression. 
5.3 Tumour Size Threshold 
Research on the metastatic potential of non-small cell lung cancers has 
consistently found that increasing tumour size is directly associated with increased 
metastases (Hubbs et al., 2010; Mujoomdar et al., 2007). This is likely related to the fact 
that the same factors that promote tumour growth also increase metastatic potential 
(Zetter, 1998). Less information is available with respect to possible lower boundaries of 
tumour size for a tumour to become metastatic or aggressive. Some research has 
suggested that the angiogenesis needed for a solid tumour to grow and become metastatic 
occurs by the time a tumour is 1-2 mm in size (Mujoomdar et al., 2007). Nodules as small 
as 1 mm were detected in the NLST. The current research found that the frequency of 
metastases increased substantially at or beyond the 10 mm tumour size, and for those 
lung tumours that met the criteria of being SA-NSCLC - only one tumour was 8 mm, and 
none were below 8 mm. The majority of metastases occurred at or beyond 10 mm and 
may identify 10 mm as an approximate lower bound for tumours to grow enough in size, 
and develop a profile, that allows the tumours to become metastatic or clinically 
aggressive. 
Using the most current version of the TNM classification system (7th edition), 
tumours less than 3 cm in size, with limited invasion of surrounding tissue, can be further 
subclassified as T1a if the tumour is less than 2 cm in long axis. If 1 cm is an 
approximate lower boundary for tumours to become aggressive and metastasize, the 
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subclassification of T1 tumours may need to be revisited to better reflect tumour biology 
and prognosis. The majority of SA-NSCLCs identified in the current research were 
detected with chest radiographic imaging, as opposed to computed tomography 
(Supplemental Material S5). While it is possible the 1 cm boundary may be a limitation 
in technology, only 3 SA-NSCLC were less than 10 mm in size, and all were detected in 
the CXR group. Lower boundaries of tumour size relating to metastatic potential and 
aggression needs to be validated by further research. 
5.4 Stage IV Lung Cancer Survival 
Tumour stage is considered the most important prognostic factor for cancer 
survivorship (Alberg et al., 2013). Amongst the most advanced (stage IV) lung cancers, 
few factors offer prognostic ability above that of tumour stage. The influence of age, 
smoking, body mass index, histology, as well as other factors, on lung cancer survival has 
been well described (Luo, Chen, Narsavage, & Ducatman, 2012; Tammemägi, Neslund-
Dudas, Simoff, & Kvale, 2003). The effects of these factors generally become washed out 
when considered amongst stage IV cancer patients (Luo et al., 2012).  
The third study aim of the current research was to investigate whether tumour size 
could have an influence on prognosis when comparing small to large stage IV lung 
cancers. In short, does tumour size have a role in prognosis amongst advanced stage 
cancers? The current research found that when comparing smaller to larger stage IV lung 
cancers, even after adjustment for smoking status, age, and histology, that tumour size 
remained a significant predictor of survival. A larger tumour (≥30 mm) carried a worse 
prognosis. This is likely related to the complications associated with a physically larger 
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tumour occupying a larger area within the lung and limiting normal organ function. Lung 
function can be compromised by larger tumours. In addition, smaller lung tumours are 
more easily treated with radiotherapy, and individuals with better lung function are better 
able to tolerate radiotherapy. Due to their overall poor prognosis, stage IV lung cancer 
survivorship is often described by percent surviving 2 years, as opposed to 5 years for 
other stages. Stage IV lung cancer has been found to have a 2-year survival of 
approximately 10-15% (Collins et al., 2007). The 2-year survival for all stage IV lung 
cancers in the NLST was approximately 16%, and was 18% for the stage IV lung cancers 
identified for study aim 3. When stratified by tumour size, 2-year survival was 16%, and 
23%, for large and small tumours, respectively. Currently, the primary consideration for 
grouping a lung cancer as stage IV is whether or not the primary lung tumour has 
metastasized. Tumour size and local invasion (T), and spread to regional lymph nodes 
(N) are not considered. If the independent effect of tumour size on stage IV lung cancer 
survival is further validated, further subclassification of stage IV cancers (e.g. stage 
IVA/stage IVB) may be useful in determining a more accurate prognosis. Overall tumour 
size should be considered an important prognostic factor even amongst stage IV lung 
cancers, where the effects of most other factors become washed out. 
5.5 Limitations 
5.5.1 Sample Size 
 Due to the case-case study design used for the current research, the NLST 
population is restricted based on a specific set of criteria, and sample size became 
relatively small. While internal validation of the models were done using bootstrapping 
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techniques to identify if resampling of the data maintained results, it is still limited to the 
sample available. Protocols were put in place in order to maximize the available sample 
including internal validation, inspecting outliers and missing data, as well as creating 
parsimonious models, where appropriate. Multiple imputations were considered, but not 
needed. The dataset used in the current study is one of the largest and most complete with 
respect to lung cancer and its risk factors, to date, and as such is believed to be optimal 
for the current research. 
5.5.2 Missing Variables 
 While many variables known or suspected to have an association with lung cancer 
development and survival are included in the current dataset, some variables are missing. 
Specifically, previous research on SA-NSCLC identified an inverse association with 
regular ibuprofen use, indicating a possible protective effect (Tammemägi et al., 2007). 
The current research could not validate this finding due to no data on ibuprofen use or 
other medication use. In addition, no information on course of treatment for lung cancer 
patients was described in the dataset. This could potentially confound the results of the 
third study aim describing differences in survivorship in stage IV lung cancer patients. 
Due to the difficult nature of properly quantifying and using occupational exposure data, 
the occupational variables contained in the dataset could not be used optimally to identify 
any potential carcinogenic contribution from environmental or occupational exposure. 
Finally, due to the high metastatic potential associated with SA-NSCLC, genetic 
information regarding the mutation profiles of the small aggressive tumours could be 
valuable in further understanding the potential familial component of this disease, and 
how it interacts with the female hormone environment. No data were available on 
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hormone levels, or hormone replacement therapy. These data were beyond the scope of 
the NLST, but may offer lines of future research that will be described later in this 
chapter. 
5.5.3 External Generalizability  
5.5.3.1 Healthy Volunteer Effect 
 The “healthy volunteer” effect describes how volunteers for prevention and 
screening trials have been found to be generally healthier, and with lower mortality, than 
the general population (Pinsky et al., 2007). This effect may bias the results of a study by 
making them look more favorable than would be found when the intervention is 
implemented in the community. The effect of this bias in the NLST has not been 
determined, but remains an important consideration for the generalizability of research 
using these data (National Lung Screening Trial Research Team, 2011a). Given that the 
associations found in the current research are believed to be biological in nature, it is not 
expected that the healthy volunteer effect would bias these results. 
5.6 Strengths 
Study strengths include the case-case design nested within a very large, relatively 
representative, and well-defined cohort: data collection was prospective, eliminating 
recall bias, and sampling cases and controls arising within the same cohort minimizes 
selection bias that might result from alternative sampling methods. 
In addition, the current study characterizes and identifies risk factors for a group 
of cancers for which very little information is known. The results of this study validate 
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previous findings and contribute new knowledge to the area of small aggressive lung 
cancers, and may guide future areas of research. 
5.7 Implications 
Given that associations are further validated, the findings of this study suggest 
additional research, in particular, identification of the gene(s), gene alterations, and 
female factors that are associated with SA-NSCLC. Knowledge of the gene-sex 
interaction and biology of SA-NSCLC might lead to a better understanding of 
carcinogenesis and cancer progression, and identification of high-risk populations that 
might benefit from screening or increased clinical monitoring and may lead to effective 
chemoprevention and improved therapeutics. The risk factors identified in the current 
research may be useful in identifying individuals for screening at high-risk of developing 
these small aggressive cancers. The current research is not based on developing risk-
prediction models, however, results from this research may identify factors that can be 
useful in the future to identify individuals at risk of developing small aggressive cancers. 
While tumour stage remains the single most important prognostic factor for lung 
cancer survival, the results of the current study indicate that primary tumour size may 
also serve as a useful prognostic indicator for use in clinical practice. Small tumour size 
remains a favorable prognostic factor even amongst inoperable tumours possibly in part 
due to the ability to be more easily treated with radiotherapy.  
5.8 Future Directions 
Given the early progression and high metastatic potential of these small 
aggressive cancers, further research into the specific mutation profile of these tumours 
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may provide valuable insight into their aggressive nature. Molecular epidemiologic 
studies may identify genes associated with familial aggregation of SA-NSCLC and how 
these genes interact with the female hormone environment. The finding of a female sex 
by family history of lung cancer interaction was first identified in the PLCO population, 
and validated in the current study using the population from the NLST. Future research 
could include retrospective analysis of healthy and malignant tissue from NLST or PLCO 
tissue banks, and potentially identify gene mutations present in SA-NSCLC. Particular 
gene mutations of interest may be those associated with adenocarcinomas, and that have 
been identified as having a possible interaction with steroid hormones (e.g. KRAS, TP53, 
etc.). 
Neuroendocrine differentiation has been identified as playing a significant role in 
small cell lung cancers, though a similar role for the prognostic and predictive ability of 
NED has not been as clearly established in non-small cell lung cancers. Evidence 
suggests a potential role of NED in the growth and invasiveness of lung tumours, 
particularly amongst adenocarcinomas. Identification of a possible neuroendocrine role in 
SA-NSCLC could provide insight into the high metastatic potential of these aggressive 
cancers. Immunohistochemical analysis of the tumour tissue could provide evidence 
regarding the role of neuroendocrine differentiation in the physiological pathway of these 
aggressive lung tumours. 
While the role of previous lung comorbidities has been identified as playing an 
important role in lung carcinogenesis, further research should investigate its role in early 
disease progression, and how inflammation-induced carcinogenesis plays a role in tumour 
growth, invasion, and metastases. 
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5.9 Conclusions 
 Overall, the current study was able to validate findings from previous research in 
a different population. This study produced novel findings with respect to the role of 
previous lung comorbidities, particularly emphysema, in early lung cancer progression 
and metastases. This study has contributed new knowledge to understanding the unique 
biological pathways of SA-NSCLC. Furthering the knowledge base surrounding small 
aggressive cancers may provide valuable insight into lung carcinogenesis, and in the 
future help to identify high-risk individuals for screening who would benefit most from a 
targeted approach. These cancers carry grave prognosis and increase mortality. Future 
research on the pathophysiology of these small aggressive cancers could help to guide 
treatment options. 
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SUPPLEMENTAL MATERIAL 
 
Figure S1. Distribution of lesion size for small aggressive non-small cell  
lung cancers (SA-NSCLC) stratified by NLST screening arm. Histogram is 
superimposed with a smooth kernel density estimate. 
 
Table S2. Distribution of cases and controls according to screening arm 
and histology. 
 CXR LDCT  
Case Status AC SqCC Other AC SqCC Other Total 
Large non-aggressive  59 51 13 42 49 6 220 
SA-NSCLC 34 7 3 15 1 0 60 
Total 93 58 16 57 50 6 280 
Abbreviations: AC, adenocarcinoma; CXR, chest x-ray; LDCT, low-dose computed tomography; SA-NSCLC, small  
aggressive non-small cell lung carcinomas; SqCC, squamous cell carcinoma. 
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Table S3. Hosmer-Lemeshow goodness-of-fit test for final logistic regression 
model (Table 10). 
Group Probability Obs. 1 Exp. 1 Obs. 0 Exp. 0 Total 
1 0.1835 5 4.2 18 18.8 23 
3 0.2422 8 8.7 28 27.3 36 
8 0.2878 18 17.8 44 44.2 62 
9 0.6011 9 10.0 8 7.0 17 
10 0.8935 8 7.2 2 2.8 10 
# Observations 148      
# Groups 5      
Hosmer-Lemeshow Χ2 0.80      
P-value 0.8501      
 
Table S4. Pearson goodness-of-fit test for final logistic regression model (Table 10). 
Group Probability Obs. 1 Exp. 1 Obs. 0 Exp. 0 Total 
1 0.1835 5 4.2 18 18.8 23 
2 0.2422 8 8.7 28 27.3 36 
3 0.2878 18 17.8 44 44.2 62 
4 0.5558 2 2.8 3 2.2 5 
5 0.6011 7 7.2 5 4.8 12 
6 0.6402 2 1.3 0 0.7 2 
7 0.6923 4 4.2 2 1.8 6 
8 0.8935 2 1.8 0 0.2 2 
# Observations 148     
# Covariate patterns 8     
Pearson χ2 2.14     
P-value  0.5429     
 
Table S5. Covariate patterns used in Pearson goodness-of-fit test (Table S4). 
Group Probability Female FHxLC Emphysema 
1 0.1835 0 1 0 
2 0.2422 1 0 0 
3 0.2878 0 0 0 
4 0.5558 0 1 1 
5 0.6011 1 1 0 
6 0.6402 1 0 1 
7 0.6923 0 0 1 
8 0.8935 1 1 1 
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Figure S6. Kaplan-Meier survival function for stage IV NSCLC in primary sample for 
study aim 3 with 95% confidence interval. 
 
  
Table S7. Log-Rank test for differences in survival functions between stage IV SA-
NSCLC and large stage IV NSCLC (Figure 1). 
Stage IV Lung Cancer Events Observed Events Expected 
Large Stage IV NSCLC 134 121.18 
Stage IV SA-NSCLC 37 49.82 
Total 171 171.00 
 Χ2 (1) 4.74 
 P-value 0.0295 
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Figure S8. Nelson-Aalen cumulative hazard function for stage IV NSCLC in primary 
sample for study aim 3 with 95% confidence interval. 
 
 
 
  
Figure S9. Nelson-Aalen cumulative hazard function stratified by stage IV SA-NSCLC and 
large stage IV NSCLC. 
 
112 
  
Figure S10. Schoenfeld residual for age at lung cancer diagnosis plotted against time with 
LOWESS curve using an 80% bandwidth.  
 
  
Figure S11. Log-log survival plot for survival probability over analysis time for stage IV 
lung cancers stratified by smoking status (current versus former).
 
113 
 
Figure S12. Log-log survival plot for survival probability over analysis for stage IV lung 
cancers time stratified by histologic subtype. 
 
 
Figure S13. Log-log survival plot for survival probability over analysis time for stage IV 
lung cancers stratified by tumour size (small versus large). 
